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1 Summary 
Obesity is one of the major healthcare problems worldwide and it is expected to increase in 
the next decades. It leads to and drives hypertension, hyperlipidaemia, and hyperglycaemia. 
These factors are components of the metabolic syndrome (MetS), which plays a major role in 
obesity-related comorbidities like type 2-diabetes mellitus (T2DM), cardiovascular disease 
(CAD) and non-alcoholic fatty acid liver disease (NAFLD). 
Roux-en-Y gastric bypass (RYGB), among different bariatric surgery techniques, is 
considered the “golden standard” procedure and the most effective therapy to achieve 
sustained and long-term weight loss and to improve obesity-related comorbidities. 
Improvements of glycaemic control, endothelial function and the lipid profile seem to be 
independent and to occur before changes in body weight. 
ApoE*3Leiden.human Cholesterol Ester Transfer Protein (ApoE3L.CETP) mice have a 
humanized-lipoprotein metabolism: they have high low-density lipoprotein cholesterol (LDL- 
C) and low high-density lipoprotein cholesterol (HDL-C). When fed a western-type diet, they 
show typical features of the MetS such as increased body weight, hyperlipidaemia and 
hyperglycaemia. Even more, they show a heterogenic response to the MetS as is a typical 
situation in human patients; hence, they are one of the best animal model available to study 
the MetS. 
In the first main study of my work, we investigated the causes of this heterogeneity in terms 
of lipid and glucose metabolism, identifying two different phenotypes, so-called responder 
mice (R) that develop dyslipidaemia and non-responder (NR) mice that do not develop the full 
dysmetabolic phenotype because of a compromised liver function. Second, we investigated 
the effect of RYGB in responder ApoE3L.CETP mice on lipid and glucose metabolism. To 
discriminate between surgical effect and body weight effects, we used Sham operated mice 
body weight-matched to the RYGB mice. 
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We showed that glucose metabolism and lipid profile improved within body weight loss, 
especially total cholesterol, non HDL-C and ceramide were greatly reduced in RYGB mice, 
indicating a body weight loss independent effect. 
Our results highlighted the usefulness of RYGB in defeating the MetS, underlining which 
effects are surgery related and which effects are body weight loss related and hence probably 
can also achieved with other methods. We believe that our data provide an important proof- 
of-concept to the advantage of using the ApoEL.CETP mouse model after RYGB in 
deciphering the metabolic improvements after bariatric surgery to treat the MetS. 
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2 Zusammenfassung 
Übergewicht ist eine der grössten Herausforderungen der Gesundheitssysteme weltweit, und 
die Häufigkeit und das Ausmass von Übergewicht werden in den kommenden Jahrzehnten 
wahrscheinlich weiter ansteigen. Übergewicht führt zu Bluthochdruck, Hyperlipidämie und 
Hyperglykämie, d.h. den wichtigsten Faktoren, die das metabolische Syndrom (MetS) 
darstellen. Das MetS seinerseits steht in direktem Zusammenhang mit Übergewicht- 
assoziierten Erkrankungen wie dem Typ 2 Diabetes mellitus (T2DM), Herz-Kreislauf- 
Erkrankungen (CAD) und Lebererkrankungen, wie der Fettlebererkrankungen, die nicht 
spezifisch durch Alkohol ausgelöst werden (NAFLD). 
Der Roux-en-Y Magenbypass (RYGB) gilt unter allen Methoden der bariatrischen Chirurgie 
als der sog. Goldstandard. Er stellt bislang die effizienteste Therapie dar, die zu einem 
deutlichen und anhaltenden Gewichtsverlust führt, und durch den auch die genannten 
Begleiterkrankungen verbessert werden. So kommt es z.B. bereits vor einem markanten 
Gewichtsverlust zu einer Verbesserung des Glucose- und Fettstoffwechsels und der 
Endothelfunktion in Blutgefässen. 
Die sog. ApoE*3Leiden.human Cholesterol Ester Transfer Protein (ApoE3L.CETP) Mäuse 
weisen einen Lipoprotein-Stoffwechsel auf, der gut demjenigen des Menschen entspricht; 
diese Mäuse haben z.B. hohes Low-density lipoprotein Cholesterol (LDL-C) und niedriges 
High-density lipoprotein Cholesterol (HDL-C). Wenn sie mit einer sog. Western-type Diät 
gefüttert werden, zeigen sie ausserdem die typischen Charakteristika des MetS, wie erhöhtes 
Körpergewicht, Hyperlipidämie und Hyperglykämie. Ebenso von Bedeutung ist die relativ 
heterogene Symptomatik des MetS unter diesen Bedingungen, was der typischen Situation 
bei Patienten entspricht. Momentan gelten diese Mäuse als das beste Nagermodell, um das 
MetS umfassend zu untersuchen. 
Im ersten Teil meines Projekts untersuchten wir die möglichen Ursachen dieser Heterogenität 
hinsichtlich Fett- und Glucosestoffwechsel, und wir charakterisierten zwei verschiedene 
Phänotypen dieser Mäuse. Einerseits die sog. Responder Mäuse (R), die eine 
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charakteristische Dyslipidämie entwickeln, und die sog. Non-responder (NR) Mäuse, bei 
denen der metabolische Phänotyp weniger stark ausgeprägt ist. Interessanterweise scheint 
dies allerdings darauf zu beruhen, dass die Leberfunktion dieser Mäuse hochgradig 
eingeschränkt ist. 
Im zweiten Teil meines Projekts untersuchten wir den Einfluss einer RYGB-Operation auf den 
Stoffwechsel der Responder ApoE3L.CETP Mäuse. Wir unterschieden dabei RYGB- 
spezifische Effekte von solchen, die rein durch die Körpergewichtsreduktion erklärt werden 
können. Wir konnten zeigen, dass der Glucose- und Fettstoffwechsel sich gewichtsabhängig 
verbesserte, dass aber z.B. die Reduktion des Gesamt-Cholesterols, des nicht an HDL 
gebundenen Cholesterols und von Ceramid nur bei RYGB reduziert waren, d.h. auf einem 
Operations-spezifischen Effekt beruhen. 
Unsere Resultate unterstreichen, dass RYGB zurecht auch als sog. "metabolische Chirurgie" 
angesehen wird, da durch RYGB erstens das MetS positiv beeinflusst wurde, und da dieser 
Effekt z.T. gewichtsunabhängig war. Wir sind davon überzeugt, dass unsere Ergebnisse einen 
wichtigen Beitrag zur Untersuchung des MetS und dessen Behandlung liefern. Ausserdem 
glauben wir, dass die ApoEL.CETP Maus ein geeignetes Modell zur Untersuchung dieser 
Aspekte des MetS darstellt. 
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3 Introduction 
3.1 Obesity 
 
Obesity epidemics counted more than 650 million obese adults (390 million women and 281 
million men) [1] and 1.9 billion overweight adults in 2016 worldwide. The World Health 
Organization (WHO) defines as overweight an adult with BMI greater or equal to 25 kg/m2 and 
as obese an adult with a BMI greater or equal to 30 kg/m2. Also childhood obesity and 
overweight increased dramatically in the past 40 years (47%) in both developed and 
developing countries [2]. 
Obesity per se results from an imbalance between calories consumed and calories expended; 
this creates a positive energy balance and results in excess body weight [3]. The aetiology of 
obesity has its roots in a complexity of genetics, environmental and cultural factors. Several 
studies with different populations [4] and with twins [5] proved that a genetic predisposition to 
gain weight exits: especially, some specific polymorphisms have been associated with an 
increased risk of obesity [6, 7]. This genetic predisposition, however, is believed to contribute 
to less than 1.5% of the entire obesity aetiology [8], and part of this genetically susceptibility 
has been shown to be overwhelmed by physically active lifestyle [9]. Nevertheless, life style 
choices and sedentary life contribute to obesity as well [3, 10]. 
 
 
3.2 Obesity and related co-morbidities 
 
Adulthood and childhood obesity are associated with other health problems as sleep, 
respiratory, gastrointestinal, endocrine, cardiovascular and psychiatric disorders [11] that, if 
developing during childhood, often persist in adulthood, lowering life style expectations by 6- 
14 years [12, 13]. Visceral obesity is one of the main factors that contributes to and drives 
hypertension, elevated plasma insulin concentrations and insulin resistance (IR), and, 
eventually, type 2 diabetes mellitus (T2DM), hypertriglyceridaemia and low levels of high- 
density lipoprotein cholesterol (HDL-C). The mentioned factors are components of the 
metabolic syndrome (or MetS) [14, 15]. In other words, the MetS describes a cohort of obesity- 
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related comorbidities such as T2DM, non-alcoholic fatty liver disease (NAFLD) and 
cardiovascular diseases (CAD). Data collected in the United States between 2003-2012 
showed increased MetS epidemics in adults over 60 years, with a generally higher prevalence 
in women compared to men and a highest prevalence in Hispanics white compared to other 
ethnicities [16]. 
Even though some pathophysiological mechanisms of the MetS are understood today, many 
factors are still unknown and it is important to investigate them to find possible treatments and 
to ameliorate the quality of life for these patients. 
 
 
3.3 Animal models for MetS 
 
It is difficult to combine all the aspect of the MetS in one single animal model. MetS has been 
defined as obesity combined with at least one other disorder as dyslipidaemia, or impaired 
glucose in different mice model [17]. It is quite common in models of obesity to have IR, as 
commonly seen in humans where increased abdominal fat correlates with increased IR. 
Commonly used mice models to describe these two features of the MetS are: leptin-deficient 
(Lepob/ob) [18], leptin receptor-deficient (LepRdb/db) [19] and yellow agouti Ay/a [20]. They have 
spontaneous genetic modifications that make them become obese, insulin intolerant, and 
hyperglycaemic, so that they eventually develop diabetes mellitus. As a consequence of a 
leptin receptor defect, the LepRdb/db mice have high leptin circulating levels that are related to 
their adiposity levels, while Lepob/ob are leptin deficient. Aguti Ay/a mice particularly displayed 
delayed obesity onset and intact leptin signalling. 
Even though these mice are severely obese and develop obesity related IR, the limiting factor 
 
of these mouse models is that they do not develop hypertension or modifications in their lipid 
profile, hence they hardly develop atherosclerosis on a high-fat diet. In fact, mice' lipoprotein 
profile consists primarily of HDL-C, while in human low density lipoprotein cholesterol (LDL- 
C) are the main lipoproteins present [17]. 
 
Because in people IR and obesity correlate with the development of dyslipidaemia [21], other 
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mice models were considered, such as LDL-C receptor knock-out mice (LDLR-/-) mice, apoE- 
deficient mice, and ApoE*3Leiden.human Cholesterol ester transfer protein (ApoE3L.CETP) 
mice. 
LDLR-/- mice [22] and apoE-deficient mice [23] develop hypercholesterolaemia on chow and 
on a HFHC (high fat high cholesterol) diet, and eventually atherosclerosis [24-26]. Data on 
obesity and IR developed in ApoE-/- mice are controversial: some studies indicated that apoE- 
/- mice do not develop obesity and IR [27, 28], while other studies indicated the opposite [29]. 
Overall apoE-/- mice are considered a good model for the MetS under HFHC diet conditions 
and the breeding of Lepob/ob or LepRdb/db on the apoE-/- background allowed to have a 
model of obesity, IR and hyperlipidaemia [17]. 
Up to know, ApoE3L.CETP mice seem to be the best available model to study the MetS since 
they present a humanized lipoprotein metabolism, develop atherosclerosis when HFHC diet 
fed, and display a human-like response when treated with statins [30, 31]. Compared to 
wildtype mice, they have higher concentrations of very low density lipoprotein (VLDL) and 
LDL-C, and relatively low concentrations of HDL-C when fed the HFHC diet. The presence of 
the ApoE3Leiden transgene hampers the uptake of VLDL remnants by the liver leading to 
increased VLDL/LDL-C levels in plasma, similar to humans [32]. Further, the introduction of 
the human glycoprotein CETP is responsible for the transport of cholesterol ester from HDL- 
C to apolipoprotein-B (apo-B) containing lipoproteins in exchange of triglycerides, leading to 
decreased HDL-C [32]. For these reasons, we used these mice in the experiments performed 
for my dissertation. 
The last aspect not always described or mentioned as a key feature of the MetS is 
hypertension. Hypertension, indeed, is not always present in all MetS patients, even if it has 
been shown to correlate in some of them with increased atherosclerosis [33]. Most of the in 
vivo studies concerning obesity and hypertension were mainly performed in rats and only a 
few in mice investigating the effects of blood pressure and diet-induced obesity, or focusing 
on the renin-angiotensin system (RAS) summarising alterations in adipokines, leptin and 
adiponectin [17, 34]. For example, Gupte et al [34] showed that blockade of the angiotensin II 
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type 1 receptor abolished hypertension; similarly, Kouyama et al [35] demonstrated that 
deficiency in the same receptor decreased diet-induced body weight gain, improves IR as well 
as hypertension. Despite these data, scientists are still debating on the inconsistency of the 
animal models in showing hypertension on one hand due to difficulties in reproducing the 
same blood pressure measurements with telemetry or with the tail cuff method [34, 36, 37], 
and on the other hand due to differences in the animals' background strain, age, gender and 
way to induce obesity [17]. For example, Lepob/ob mice (on the C57BL/6J background) were 
found to be hypotensive [38] while some LepRdb/db mice were reported to be either hypotensive 
or hypertensive [39]. 
In humans, instead, the role of RAS in the MetS is well demonstrated and clinical data showed 
that pharmacological inhibition or blockade of enzymes in the RAS system (as e.g. angiotensin 
converting enzyme inhibitors or angiotensin receptor blockers [40, 41]) are not only the first 
line treatment for hypertension in obese patients, but also they can improve insulin sensitivity 
highlighting their applicability in treating MetS patients [17]. 
Nevertheless, clinical and animal studies proved the importance of RAS in some aspects of 
the MetS, confirming a connection between obesity and hypertension and the importance in 
investigating also this aspect. 
 
3.3.1 ApoE3L-CETP mice: our model used to describe the MetS; differences between 
responder (R) mice and non-responder (NR) mice 
 
ApoE3L.CETP mice, commercially available at TNO (TNO innovation for life, Leiden, The 
Netherlands) exhibit a dyslipidemic phenotype combined with obesity, IR, and atherosclerosis 
when administered HFHC diet [42-45]. Responses of ApoE3L.CETP mice to the HFHC diet 
were reported to be highly variable [46] and therefore an attempt was made to clarify the 
causes of the observed heterogeneity inherent to this model; hence, the ApoE3L.CETP mice 
can be clustered into two different phenotypes within the same genetic background in 
ApoE3L.CETP mice: responder (R) mice and non-responder (NR) mice. 
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Mice that do not fully display the expected MetS phenotype, i.e., increased body weight and 
increased triglycerides and total cholesterol levels after HFHC diet exposure, are classified as 
NR and represent approximately 20% of the total ApoE3L.CETP mice population at TNO 
(TNO innovation for life, Leiden, The Netherlands, personal communication). In fact, NR mice 
and R mice can already be differentiated at young age when chow fed, based on their 
prevailing triglyceride and cholesterol plasma levels. Hence, chow fed mice at 6-7 weeks of 
age with triglycerides levels lower than 2 mmol/L (i.e. 177 mg/dL) are considered as NR mice, 
while those with triglycerides levels above this arbitrary threshold are classified as R mice. 
 
 
3.4 HDL metabolism and obesity 
 
HDL-C plays a very important role in MetS. HDL-C is involved in cholesterol homeostasis 
because it mediates the transfer of cholesterol from extra-hepatic tissues to the liver; excess 
cholesterol is removed from peripheral tissues, preventing its accumulation and 
atherosclerotic plaque formation (Fig 1). Hence, HDL-C has a protective and anti-atherogenic 
action that is determined not only by its concentration, but even more importantly by its 
properties [47]. 
HDL-C forms are a heterogeneous class of lipoproteins divided in several subclasses defined 
by density, size, shape and by their lipid and protein composition [48]. HDL-C subclass 
distribution was firstly described in early 1950s by De Lalla et al [49] by ultracentrifugation and 
HDL2-C and HDL3-C were defined. Particularly, HDL2-C are less dense (1.063-1.125 g/mL) 
are relative rich in lipids while HDL3-C are more dense (1.125-1.21 g/mL) and relative rich in 
proteins. Considering their gel electrophoresis mobility, based on their particle size, Nichols 
et al [50] fractioned HDL2-C and HDL3-C in: HDL3c -C (7.2-7.8 nm diameter), HDL3b -C (7.8- 
8.2nm), HDL3a -C (8.2-8.8 nm), HDL2a -C (8.8-9.7 nm) and HDL2b -C (9.7-12.0 nm). 
HDL-C formation starts in the hepatocytes or in the enterocytes. Apo A-I secreted by the 
intestine and the liver interacts functionally with ABCA1 allowing the transfer of phospholipids 
and cholesterol to lipid-poor apo A-I. Lipidated apo A-I are converted first in discoidal particles 
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enriched in un-esterified cholesterol, and second in spherical HDL particles [51, 52] (Fig 2). 
Apo E and apo A-IV are also involved in the biogenesis of HDL-C [53, 54]. These lipid-free 
apolipoproteins or lipid-poor particles are in continuous evolution and allow hepatic and non- 
hepatic cells to acquire and exchange phospholipids and un-esterified cholesterol [55]. CETP 
mediates the transfer of triglycerides from VLDL and chylomicrons that are rich in triglycerides 
to HDL particles. The increase in circulating VLDL promotes triglycerides transfer to HDL-C 
particles, mainly HDL2-C increasing HDL uptake [56]. 
The strong inverse relationship between the plasma concentration of HDL-C and the 
increased risk of developing coronary artery disease in the context of the MetS raised interest 
in better understanding the mechanisms underneath [57]. It had been shown that genetic, 
lifestyle and environmental factors contribute differently in lowering HDL-C plasma levels [58- 
60]. 
In obese subjects, HDL-C levels are decreased, HDL-C becomes dysfunctional, and together 
this increases the risk of cardiovascular disease and related comorbidities [61]. In particular, 
dysfunctional HDL-C loses its anti-oxidant function, has lower endothelial protective activity 
[62] and a reduced capacity of promoting cholesterol efflux [63]. Hence, obesity particularly 
lowers HDL2-C [64] and increases free fatty acids release from adipose tissue into the 
circulation providing a substrate for the formation of more VLDL particles by the liver [65]. This 
increases CETP activity lowering HDL2-C and increasing VLDL. 
Pharmacological inhibition of CETP activity with CETP inhibitors has been proposed as a 
therapeutic strategy in increasing HDL-C levels, but they failed in phase III of clinical trials, 
because of increased cardiovascular morbidity and mortality [66]. 
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Fig. 1: Cholesterol homeostasis. 
Cholesteryl ester transfer protein (CETP) mediates the exchange between triglycerides (TG) 
and lipoproteins of cholesterol ester (CE). CE are transferred into apolipoprotein B-containing 
low density lipoprotein (LDL-C) to form very low density lipoprotein (VLDL) to more 
atherogenic, readily oxidized LDL particles, that cojntribute to macrophage foam cell 
formation. ATP-binding cassette transporter A1/G1 (ABC-A1/ABC-G1) and Scavenger 
Receptor class B member 1 (SR-B1) mediate cholesterol efflux out of the peripheral 
macrophage to nascent, pre β-HDL-C, that matures to larger HDL via lecithin/cholesterol 
acyltransferase action [67] [68]. 
 
 
 
Fig 2: Representation of the biogenesis of HDL containing apo A-I, apo E or apo A-IV. 
The interaction between secreted apo A-I and ATP- binding cassette transport 1 (ABC-A1) 
allows phospholipids (PL) and free cholesterol (FC) to be transferred to lipid-poor apo A-I. 
These lipidated apoproteins (pre β-HDL-C) are converted into discoidal particles enriched in 
unesterified cholesterol. The enzyme lecithin/cholesterol acyltransferase [67] converts 
discoidal HDL into spherical HDL particles [51]. 
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3.5 Glucose metabolism and obesity 
 
Overweight and obesity are two conditions that induce alterations in glucose metabolism: 
according to Colditz et al. [69], an increase of body weight by 1 kg is related to an increased 
risk for developing T2DM of 9%. 
Glucose metabolic alterations include IR that precedes the development of T2DM, and it is 
usually associated with hypersulinaemia as a compensatory mechanism to maintain 
normoglycaemia [70]. It has also been proposed by several research groups that IR and 
hyperinsulinemia are associated with increased VLDL-C/triglycerides levels, low HDL-C levels 
and hypertension, and all of these factors may directly contribute to the progression of T2DM 
[71] and cardiovascular dysfunction [72]. In fact, IR increases lipolysis and reduces 
adipocytes’ glucose uptake leading to hyperlipidaemia and fatty organs, in other words 
adipocytes lose in part their ability to convert carbohydrate in lipid to store [73]. 
Even if a strong correlation between a metabolic abnormality (e.g. overweight, obesity, 
hypertension, hyperlipidaemia) and the risk of developing T2DM had been demonstrated by 
Janghorbani et al [74], research to identify new biomarkers or criteria to predict T2DM or CAD 
onset at early stages is still ongoing. Townsend et al [75] particularly highlighted the problem 
of healthy adults undiagnosed for IR or hyperinsulinaemia prior to the disease development. 
Up to now measuring dysglycaemia in fasted or postprandial states, as well as fasting insulin 
or insulin during oral glucose tolerance test (OGTT) have been proposed to try to predict early 
onset of T2DM [75]. 
 
 
3.6 Treatment for the MetS 
 
The main goal for obese patients with the MetS is to improve their quality of life and to prolong 
their life expectancies, reducing atherosclerosis and diabetes and other comorbidities. Caloric 
restriction is always recommended and it is beneficial in the reduction of the MetS 
complications, along with adjustments of physical activity, but this is not sufficient on a 
population levels [76, 77]. In clinical studies, weight loss of 5-10% due to lifestyle intervention, 
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as diet or exercise, can already improve insulin resistance and lipid levels [77] and is so-called 
first-line MetS treatment [78]. According to the National Institutes of Health [79] guidelines for 
the treatment of obesity pharmacological intervention, also so-called second-line treatment, is 
necessary when patients have a BMI > 30 or > 27 kg/m2 with comorbidities [80]. At present, 
new pharmacological approaches are being developed for the long-term treatment and aim to 
induce body-weight loss, weight maintenance, and reduced fat mass in combination with 
reduction in lipids or glucose levels [78, 81]. Bariatric devices and bariatric surgery are 
considered third- and fourth-line treatments for the MetS even if to date success of surgical 
interventions largely outweighs the success of diet or pharmacotherapy. 
 
 
3.7 Bariatric surgery 
 
Bariatric surgery is considered a gold-standard treatment for MetS that leads to improvement 
and remission of diabetes, reduction of CAD risk, sustained and maintained body weight loss 
and improvement of the quality of live and prolonged survival [82, 83]. It is recommended for 
patients with a BMI ≥ 35 kg/m2 with at least one comorbidity (particularly T2DM) or a BMI ≥ 40 
kg/m2 without such comorbidities [84]. 
Nowadays gastric banding (GB), sleeve gastrectomy (SG), Roux-en-Y gastric bypass 
(RYGB), biliopancreatic diversion with duodenal switch (BPD-DS) and mini gastric bypass 
(MGBP) are the most effective therapies for obesity and its comorbidities (Fig 3-4). 97% of all 
bariatric surgery performed in the USA are done laparoscopically, allowing a quicker recovery 
period, reduction of post-operative pain and wound-related complications if compared to 
standard open surgery procedures [85, 86]. Hence, mortality associated with bariatric surgery 
had been reported to be lower than 0.1-0.3% [87, 88] thanks to the introduction of the 
laparoscopic approach [89]. 
Surgical capacity, and surgical post-operative care costs are still the main limiting factors that 
allows only <1% of the USA and worldwide population who would be eligible for bariatric 
surgery to be actually operated; nevertheless, in the past 2 decades in USA, the number of 
16  
surgery cases increased from 158’000 in 2001 to 193’000 in 2014 [90]. While in the USA the 
most common procedure is SG, worldwide RYGB (45%) and SG (37%) are the most common 
bariatric procedure performed [91]. 
Bariatric surgery per se was proposed for the first time in the mid-1960s by Edward Mason as 
the most effective procedure to achieve weight loss [92]. Particularly a single loop 
anastomosis was described as the first gastric bypass, later modified into the current RYGB 
[82]. In the early 1980's, other bariatric surgery procedures started to being developed taking 
into consideration different ways of portioning the stomach and of reconstructing the small 
intestine, so-called biliopancreatic diversion and with the addition of the duodenal switch [93]. 
Even if SG had been initially proposed as the initial step of a two-stage approach in RYGB or 
MGBP [94], given its success as a bariatric operation in the late 2000s it has been established 
by the FDA (U.S. Food and Drug Administration) as one of the bariatric surgery procedures 
available [82]. 
Alternative and less invasive approaches have been proposed in the past couples of years to 
induce body weight. For example, in 2015, FDA approved vagal nerve blockade devices to 
treat severe obese patients (BMI 35-45 kg/m2) since it has been shown that blockage of the 
vagal nerve may induce body weight loss [82, 95]. 
Different endoscopic bariatric surgeries and new devices are currently in development and 
close to being approved by the FDA. The main actions are related to restriction or manipulation 
of the stomach or to neuro-hormonal alterations or a combination of the two. For example, the 
single and the integrated dual intra-gastric balloons were approved by FDA in 2015 to treat 
obese patients with a BMI of 30-40 kg/m2 [96]. Only 6% of patients up to now developed 
complications as abdominal pain, gastro-esophageal reflux or gastric ulcers that could lead to 
balloon removal. Long-term and severe complications results are not yet available due to the 
novelty of the technique [82]. 
17  
 
 
 
Fig 3: Gastrointestinal anatomy after different bariatric surgery procedures: 
(a) Roux-en-Y gastric bypass (RYGB), (b) Gastric banding (GB), (c) Sleeve gastrectomy 
(SG) and (d) Biliopancreatic diversion with duodenal switch (BPD-DS) [82]. 
(b) 
 
 
Fig 4: Schematic representation of mini gastric bypass [97] 
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3.7.1 Gastric Banding 
 
Gastric banding (GB) (Fig 3b) was commonly used in last 20 years, but it has been gradually 
substituted by SG and RYGB due to the demand for revision or conversion to other bariatric 
surgery procedures in one in five patients, and because more invasive procedures proved to 
be more efficient [98, 99]. During the GB surgery, an adjustable silicon band is placed around 
the stomach, just below the gastro-esophageal junction and securely fixed with proper sutures. 
Adding or removing saline through a subcutaneous port allows adjustment of the size of the 
silicon banding, hence controlling/limiting food intake [100]. For the first 6 week post-surgery, 
patients normally receive a liquid or semi liquid diet, then a normal diet. 
After GB patients progressively lost weight, had reduced HbA1c levels (33% patients who 
underwent GB reached HbA1c below 6.5% after 1 year) [101], reduced diastolic and systolic 
blood pressure, and showed a modest improvement in total cholesterol and triglycerides. 
Nonetheless, changes in body weight could not always predict changes in any of the metabolic 
parameters mentioned above. 
The main complications described are band slippage or prolapse (with an incidence of 22%) 
[98], band infection, tube disconnection and band erosion (incidence of 11%) [102]. Compared 
to other bariatric surgery techniques it is safer, less invasive with a shorter operating time, 
shorter hospitality stay and fewer short-term complications [100] and with a mortality risk 
almost close to zero [101]. Since, it has also been shown that some patients reached diabetes 
remission after 2 years with a combined multidisciplinary team care [103], GB is still 
considered a valid treatment for MetS [101]. 
 
 
3.7.2 Sleeve Gastrectomy 
 
Sleeve Gastrectomy (SG) (Fig 3c) is today one of the most commonly used procedures to 
achieve long term body weight loss in the United States, and it consists of an excision of the 
greater curvature of the stomach (80%), leaving a tubular stomach or sleeve [98, 104, 105]. It 
is relatively simple compared to other bariatric surgery techniques since no bypass 
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anastomosis is needed and the rest of the gastrointestinal tract is left intact [106], and it is 
generally offered to super-obese patients with a BMI > 60 kg/m2 [107]. SG induced reduction 
of daily caloric intake [108], and improvements in glucose and lipid metabolism [109], even if 
with lower effects compared to RYGB. Although glucose homeostasis improved after SG, with 
levels of HbAc1 <6%, to maintain normal glycaemia SG patients still needs drugs [110] and 
T2DM is not always remitted [111, 112] . 
Complications to SG are related to leakage along the staple line and to strictures. Leakage 
(incidence of 3% for primary procedures and 10% for revisional procedures) can induce 
peritonitis and sepsis; strictures, as kinking or twisting of the tubular pouch, can induce inability 
to tolerate oral intake; dysphagia, reflux [113]; post-surgery haemorrhage (3.57%) [107]. 
 
 
3.7.3 Biliopancreatic diversion with duodenal switch 
 
Biliopancreatic diversion with duodenal switch (BPD-DS) (Fig 3d) consists of two different 
components. Initially a vertical gastrectomy is performed, similarly to a SG, to create a tubular 
gastric pouch, then a large portion of the small intestine (50%) is bypassed creating 
malabsorption [82]. At approximately 250 cm to the ileocaecal valve a segment of the distal 
ileum is divided and anastomosed to the duodenum. Then a second anastomosis is created 
at 100 cm approximately to the ileocaecal valve. Since most the small intestine is bypassed, 
decreased absorption of protein, fat, nutrients and vitamins occurs [82], but also improvement 
in glucose metabolism [114]. Hence, it is considered the most effective treatment for severe 
obesity and T2DM when compared to the other bariatric surgery procedures [115]. Short-term 
complications (e.g. leakage or obstructions) and long-term complications as nutritional 
deficiencies limited a wider use of this technique [93, 116]; only about 1% of all bariatric 
surgery performed in the USA consist of BDP-DS [90] and it is used for patients with a BMI > 
50kg/m2 or with weight regain after other bariatric operations [82]. 
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3.7.4 Mini Gastric Bypass 
 
The laparoscopic mini gastric bypass (Fig 4) firstly reported by Rutledge et al [117] recently 
gained popularity since it allows to achieve similar results as RYGB and since its procedure 
is technically less demanding with shorter hospitalization and fewer post-operative 
complications [97]. 
Initially, the stomach is divided between the body and the antrum of the stomach, without 
modifying the gastric vessels. Then a small intestinal segment, about 200 cm distal to the 
ligament of Treitz, is selected and anastomosed to the stomach [118] (Fig 4). 
Mini-gastric bypass induced substantial body weight loss and improvements in glucose 
metabolism, hence it is a promising technique compared to RYGB given the safer and easier 
procedure [97]. Clinical data collections around this procedure are still ongoing to better 
understand the underlying mechanisms around changes in lipoprotein profile and bile acids 
and to have a complete long-term follow up [97]. 
 
 
3.8 Roux-en-Y Gastric Bypass 
 
The Roux-en-Y gastric bypass (RYGB) (Fig 3a) is considered the “gold standard” weight-loss 
procedure worldwide [119]. It divides the stomach into an upper pouch sized of 15-30 mL and 
a gastric remnant. The gastric pouch is anastomosed to the mid-jejunum through a gastro- 
jejunal anastomosis. The rest of the stomach and the duodenum are viable, bypassed and 
reconnected to the distal jejunum. This procedure creates a Y-shape structure in the intestine 
where almost undigested food goes through the gastric pouch and the so-called alimentary 
(or Roux) limb, while pancreatic, gastric juices and bile acids pass through the bypassed 
duodenum, also called biliopancreatic limb. These two limbs reconnect together in the so- 
called common channel, that is the last part of the small intestine. This change in the gastro- 
intestinal tract physiology may induce fat malabsorption at least when diets high in fat content 
are fed, and to some degree, it decreased micronutrient absorption, leading to for examples 
to iron and calcium deficiency, making lifelong supplementation a necessity [120, 121]. Since 
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this is the surgical technique performed for the purposes of the experiments described in my 
dissertation, specification about the effects of RYGB surgery on lipid and glucose metabolism 
will be extensively discussed in paragraphs 3.8.2 and 3.8.3; a general overview of the 
beneficial effects of RYGB is schematised in Fig 5. 
Also for Roux en-Y gastric bypass (RYGB) one of the major complications that occur is related 
to staple line leakage, reported at present in less than 2% and with a higher frequency in the 
gastro-jejunal anastomosis [122]. In some cases, also bowel obstruction and internal hernia 
were reported with an incidence between 1-16% [98, 123, 124]; it can occur at time while 
marginal ulceration has an incidence of 1-16% in open RYGB and 7% after laparoscopic 
RYGB [98, 125]. 
 
 
 
Fig 5: Schematic illustration of the physiological mechanisms after RYGB surgery. 
These mechanisms involve gastrointestinal effects (inner circle), systemic effects (middle 
circle) and behavioural effects (outer circle). Image adapted from Lutz et al, 2014 [126]. 
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3.8.1 RYGB and mechanisms involved in body weight loss 
 
RYGB procedure induces rapid and sustained body weight loss mainly due reduction in eating 
and mainly increased energy expenditure in rodents [126]. One of the key point that indicate 
body weight loss, is the loss of excessive fat mass because the body rearrange its body weight 
control “setting” [126, 127]. Body weight loss after RYGB is dependent from patient to patient; 
typically, T2DM patients lose on average 20% of their total body weight, while heavier patients 
lose much more [128, 129]. 
RYGB reduces eating in part by reducing meal size [130] and hunger sensation [131], and 
changes in food preferences [130]. 
Even though mice studies showed increased energy expenditure after RYGB [132, 133], data 
in humans are controversial. Some studies showed that energy expenditure decreased in 
patients with a normal preoperative metabolic rate [134], but it tended to increase in patients 
that were hypo-metabolic before surgery [133]. It is believed that discrepancies in the data 
might be due to different methodology in measuring energy expenditure [130]. 
 
 
3.8.2 RYGB and lipid metabolism 
 
All bariatric surgery procedures reduced total cholesterol and triglycerides at different levels. 
Perhaps different from other surgical procedures, Osto et al. [135] demonstrated that RYGB 
induces improvements in hyperlipidaemia independently and prior to any substantial body 
weight loss. As a matter of fact, total cholesterol, triglycerides and LDL-C levels decreased 
after already 1 month after RYGB surgery, indicating a direct surgical effect per se because 
the same had not been seen in sham-operated weight matched controls [136]. 
Several hypotheses have been proposed to explain how RYGB reduces directly lipid levels. 
The so-called exogenous hypothesis refers to changes in exogenous lipids sources, reduction 
in food intake and loss of appetite [137]. In fact, RYGB causes a delay in food mixing and 
digestion. It further induces reduced preference for high-fat food [138, 139], changes in lipid 
absorption [140], and modification in the gut microbiota [141]. In fact, it has been reported a 
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reduction of intestinal cholesterol and increased faecal fat levels after RYGB surgery [142, 
143], and that alterations in the intra-luminal viscosity of the gut might reduce lipid absorption 
[144]. 
The second hypothesis, or endogenous hypothesis, takes into account modifications in gut 
hormones, for example GLP-1 [145] and insulin which impacts lipolysis [146]. In other words, 
this theory stated that the delivery of not completely digested food or nutrients to the distal gut 
increased the secretion of insulinotropic and appetite-controlling gut hormones, inducing 
increased body weight loss and improved glucose and lipid metabolism [136]. Particularly, it 
has been shown that due to reduced energy intake post-surgery insulin levels decrease and 
inhibition of lipolysis is reduced [147]. 
Moreover, several studies reported greater improvement in HDL-C levels after 1, 2 and 10 
years of follow up after RYGB surgery with respect to a general improvement in total 
cholesterol and triglycerides levels [110, 148, 149]. Nonetheless, body weight loss and body 
weight maintenance per se might help in the process of increasing HDL-C plasma levels [150]. 
Indeed, HDL-C levels after RYGB surgery not only increased in respect to their concentration, 
but a shift towards remodelling into more mature particles [151, 152] with a higher anti- 
oxidative potential [152] and higher content of the anti-atherogenic apolipoprotein apo A-1 was 
also shown. The main reasons why apolipoproteins increased after RYGB find their 
explanations in enhanced intestinal secretion, increased hepatic synthesis and reduced 
catabolism [153, 154]. 
In the last decades, the role of sphingolipids and phospholipids as regulators of lipid 
metabolism and biomarkers for atherosclerosis raised its attention [155]. Notably, already 3 
and 6 months after RYGB surgery, ceramide levels decreased within body weight loss, and 
nicely correlated with improvements in CAD risk, in insulin sensitivity and glucose homeostasis 
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3.8.3 RYGB abd glucose metabolism 
 
75-85% of obese diabetic patients who underwent RYGB surgery had resolution of T2DM, 
normal blood glucose and glycated haemoglobin levels with discontinuation of diabetes- 
related medications [148]. These improvements occur within few days after surgery and even 
before weight loss occurs [156]. The main mechanisms around glycaemic metabolism 
improvement are not completely understood, and several hypotheses were advanced. The 
first one takes in consideration the hypocaloric intake diet after surgery [157], followed by 
decreased liver fat that reduces hepatic insulin resistance. Second, improved B-cell function 
occurs as a consequence of the increased sensitivity to glucose and increase in GLP-1 
secretion [158]. 
Another approach addresses the improvements in glucose metabolism after RYGB with the 
so-called hindgut versus foregut hypothesis. The hindgut hypothesis considers the 
accelerated delivery of chyme into the distal intestine to improve GLP-1 secretion that 
consecutively improves glucose metabolism [159]. Hence, GLP-1 is believed to affect directly 
the proliferation and anti-apoptosis of pancreatic B-cells [160]. In the foregut hypothesis, 
improvements of glucose metabolism are believed to depend on the fact that the duodenum 
and the proximal jejunum are bypassed which would prevent the secretion of a signal that 
reduces insulin sensitivity and hence that promotes T2DM [161]. Up to now, evidences for 
both theories have been provided. 
Further studies also focussed on the side effect of postprandial glycaemic peaks followed by 
hypoglycaemic symptoms in T2DM remitters after RYGB [162]. Data available during 
continuous glucose monitoring in patients after RYGB could not completely clarify the 
underlying cause of these abnormalities but only highlight the pharmacological implementation 
to minimize them [163]. Despite these problematics RYGB has been proposed as a treatment 
for diabetic and obese patients [83]. 
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4 Hypothesis, aims and experimental design 
4.1 Hypothesis 
 
Several clinical findings showed that RYGB improves the pathophysiology of the MetS: body 
weight loss, reduced cardiovascular risk factors, T2DM remission, and reduced mortality. 
Based on these findings, we wanted to elucidate the long-term effects of RYGB surgery on 
the improvement of lipid and glucose metabolism in ApoE*3Leiden.CETP mice, a murine 
model for the MetS. 
 
4.2 Aims and experimental design 
 
Aim 1: Characterization of the effects of long-term access to a high fat high cholesterol 
diet in the ApoE*3Leiden.CETP mouse model on feeding behaviour, glucose and lipid 
metabolism: comparison between responder and non-responder mice 
 
 
To investigate glucose and lipid metabolism, male ApoE*3Leiden.CETP responder and non- 
responder mice were chow fed for 2 weeks, followed by a high fat (60%) high cholesterol 
(0.25%) diet for 20 weeks. Mice were subjected to OGTT (oral glucose tolerant test) and IST 
(insulin sensitivity test) and to blood sampling to measure lipids profile. Baseline tests were 
performed when mice were chow fed, and then every month when they were fed the HFHC 
diet. A separate cohort of ApoE*3Leiden.CETP responder and non-responder mice were 
housed in an automated cage system to measure feeding behavior. Finally, extensive 
metabolic and histologic liver analysis of these two phenotypes were performed. 
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Fig 6: Design of the experiments under Aim 1 
OGTT, oral glucose tolerance test; IST, insulin sensitivity test; blood, blood sampling; sacrifice, 
organ harvesting, terminal blood sampling 
 
 
 
Aim 2: Effects of RYGB surgery in obese male ApoE*3Leiden.CETP mice on glucose 
and lipid metabolism: comparisons between RYGB and sham operated mice 
 
 
To study the effects of RYGB surgery on glucose and lipid metabolism, male 
ApoE*3Leiden.CETP mice were fed HFHC diet for 8 weeks prior to perform RYGB or sham 
surgery. 
Glucose metabolism was tested with OGTT and IST while lipid metabolism was analysed 
through blood sampling. Tests were performed before surgery, that is when mice were chow 
fed, and after 6 weeks of HFHC diet; and then about three weeks after surgery. 
20 days after surgery mice were sacrificed and RYGB effects were assessed on liver and 
pancreas histology. 
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Fig 7: Design of the experiments under Aim 2 
OGTT, oral glucose tolerance test; IST, insulin sensitivity test; blood, blood sampling; sacrifice, 
organ harvesting, terminal blood sampling 
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5 Results 
5.1 Original research article: “Phenotypical heterogeneity in respodner (R) and non- 
responder (NR) male ApoE*3Leiden.CETP mice” 
This section contains an original research article that was submitted to American Journal of 
Physiology - Gastrointestinal and Liver Physiology in March 2018 and it is currently in revision. 
It contains part of the studies performed for the completion of the present PhD thesis. 
 
 
My contribution, as first author of this article, includes the study design, data acquisition, data 
analysis and interpretation, and writing and revising the manuscript 
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Abstracts max 250 words 
 
The metabolic syndrome (MetS) is a major health issue worldwide and is associated with 
obesity, insulin resistance, and hypercholesterolemia. Several animal models have been used 
to describe the MetS, however many of them do not mimic well the MetS pathophysiology in 
humans. To overcome this limitation, ApoE*3Leiden.CETP mice with a humanised lipoprotein 
metabolism were developed ten years ago and they are still been used to describe the MetS. 
A heterogeneous response to Western type diet feeding has been reported in these mice: 
responder (R) mice show increased body weight, and cholesterol and triglycerides levels, 
while NR mice do not show this expected phenotype. 
The aim of this study was to characterize the differences observed in the two cohorts, 
investigating in detail feeding behavior, body weight gain, glucose tolerance, and lipid 
parameters, along with liver histology. 
Our data confirmed that only R mice resemble the pathological features of human MetS. NR 
mice develop instead a severe inflammatory hepatic condition, which affects liver function and 
prevents them to develop the expected metabolic features of the MetS. 
We conclude that R mice and NR mice exhibit prominent metabolic and morphological 
differences. Hence, it is critical to properly separate them to decrease heterogeneity in the 
data. Clinical chemistry and histological analysis can be used successfully to identify the 
phenotype, and for retrospective classification of the animals. Moreover, we point out that NR 
mice may not be an appropriate control for studies involving ApoE*3Leiden.CETP R mice. 
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Introduction 
 
Obesity in humans (defined as Body Mass Index, BMI>30 kg/m2) is one of the major health 
problems worldwide and is expected to increase even more in the next decades [1]. Although 
genetics factors are known to be involved in the pathogenesis of obesity [2, 3], its onset in the 
majority of people is due to excessive energy intake combined with a lack of physical activity. 
Obesity is often associated with other comorbidities such as cardiovascular diseases (CAD) 
[4], type 2 diabetes mellitus (T2DM) [5], hypertriglyceridemia [6], and non-alcoholic fatty liver 
disease (NAFLD) [7]. Together these conditions form the metabolic syndrome (or MetS). Since 
obesity may induce insulin resistance or changes in lipoprotein metabolism, it may be 
considered the major driving force behind the MetS [9]. While not all the underlying 
pathophysiological mechanisms are completely understood, the number of MetS patients 
increases [10]. Thus, understanding and deciphering these mechanisms will hopefully provide 
new means to counteract the MetS epidemic. 
 
 
Several animal models, such as the diet-induced obese (DIO) mouse [11], the leptin-receptor 
deficient db/db mouse [12] or the Zucker rat [13], have been used in the past decades to try 
to understand the consequences of a Western type diet on metabolism; however they typically 
do not develop all aspects of the MetS; in particular, the underlying genetic defects in the 
db/db mouse and the Zucker rat do not replicate the typical human pathophysiology. 
Moreover, there are animal models in which features of the MetS [14] develop spontaneously 
on chow diet as for example in the DahlS.Z-Lepr+/Lepr+ rat [15], the Nile grass rat [16] or ZDSD 
rat [17]. This does not occur in human patients, who rarely show sign of the MetS when fed a 
balanced low fat diet; usually, only when eating a Western type diet, the typical MetS 
symptoms develop. Taking this into account, in our studies, we used the double transgenic 
mouse model ApoE*3Leiden.human Cholesterol ester transfer protein (ApoE3L.CETP). The 
ApoE3Leiden mutation [18, 19] and the introduction of human CETP gene [19] make these 
mice' lipoprotein metabolism more similar to humans thus making them one of the best animal 
models available to assess lipid metabolism in response to a Western type diet (e.g. a 60% 
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high fat supplemented with 0.25% cholesterol (HFHC) diet) [18, 19]. Hence, these mice show 
a humanized lipoprotein metabolism, develop atherosclerosis when fed HFHC diet, and 
display a human-like response when treated with statins [20, 21]. Compared to wildtype mice, 
they have higher concentrations of very low density lipoprotein (VLDL) and low density 
lipoprotein cholesterol (LDL-C), and relatively low concentrations of high density lipoprotein 
cholesterol (HDL-C) when fed the HFHC diet. The presence of the ApoE3Leiden transgene 
hampers the uptake of VLDL remnants by the liver leading to increased VLDL/LDL-C levels in 
plasma, similar to humans [19]. Further, the introduction of the human glycoprotein CETP is 
responsible for the transport of cholesterol ester from HDL to apolipoprotein-B (apo-B) 
containing lipoproteins in exchange of triglycerides, leading to decreased HDL-C [19]. 
The major aim of this study was to characterize the effect of long-term access to the HFHC 
diet in the ApoE3L.CETP mice on feeding behavior, and glucose and lipid metabolism. 
Interestingly, responses of ApoE3L.CETP mice to the HFHC diet are highly variable and 
therefore an attempt was made to clarify the causes of the observed heterogeneity inherent 
to this model. Our study highlighted in detail the presence of two different phenotypes within 
the same genetic background in ApoE3L.CETP mice: responder (R) mice and non-responder 
(NR) mice. 
We characterized the morphological, metabolic and functional aspects of these two 
phenotypes through an extensive metabolic and histologic liver analysis of this mouse model. 
Our data indicate that only R ApoE3L.CETP mice recapitulate adequately the salient 
pathological features of human MetS. NR mice develop instead a prominent inflammatory 
hepatic condition that has detrimental effects on liver function, and may prevent the 
development of the expected “MetS phenotype”. Hence, the results of this study indicate that 
the high heterogeneity observed in this model might affect study outcomes, without an 
accurate distinction being made between R and NR animals. 
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Material and Methods 
 
Animals and husbandry 
 
Male ApoE3L.CETP mice (TNO, Innovation for Life, The Hague, Netherlands) [19, 22] aged 
7-19 weeks were used in all experiments. Prior to be delivered to our facility, 6-7 weeks old 
mice kept on a standard chow diet were tested by TNO for plasma total cholesterol and 
triglycerides levels; mice with triglycerides levels lower than 2 mmol/L (i.e. 177 mg/dL) were 
considered as NR mice, while those with triglycerides levels above this arbitrary threshold 
were classified as R mice. In the cohorts used in our experiments, particularly, NR mice had 
total cholesterol levels between 1.4 – 2.2 mmol/L (i.e. 54.1 - 84.9 mg/dL), and triglycerides 
between 0.6 - 1.9 mmol/L (i.e. 53.1 - 168.1 mg/dL), while R mice total cholesterol was higher 
than 1.9 mmol/L (i.e. 73.4 mg/dL) and triglycerides higher than 2.1 mmol/L (i.e. 185.8 mg/dL) 
at 6-7 weeks of age. For consistency, we will report henceforth our study data only in mg/dL 
units, and refer to both mmol/L and mg/dL only for data collected at TNO. 
Two different cohort of R mice and NR mice were ordered from TNO. Upon arrival at our 
 
facility, per each cohort, mice were separated into R ApoE3L.CETP mice and NR 
ApoE3L.CETP mice, and group housed at a temperature of 21°C with a 12h light-dark cycle 
(light on 2:00 am, light off 2:00 pm). They were acclimated to the new housing and 
environmental conditions for 2 weeks prior to the start of the experiments. During the 
acclimation period and for the following 2 weeks, mice were fed chow diet (4.5% fat; #3436, 
Kliba Nafag, Kaiseraugst, Switzerland) after which they were switched to a high fat high 
cholesterol diet containing 60% kcal fat and 0.25% cholesterol (D14010701, HFHC diet, 
Research Diets, New Brunswick NJ, USA) until the end of the experiments. In table 1 it is 
summarized the experimental design. The Cantonal Veterinary Office of Zurich approved all 
the animal experiments (licence 122/2014). 
 
 
Animal health 
 
Mice imported from TNO were negative for endo- and ectoparasites, viruses and bacteria, as 
indicated by the latest FELASA-compliant health reports (results not shown). Sentinel mice at 
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our facility were tested quarterly and resulted negative for major etiologic agents. Additional 
testing was conducted to confirm the specific pathogen free health status for Helicobacter spp. 
using qPCR on pooled frozen liver samples obtained from R mice and NR mice used in this 
study (n=3). The qPCR analysis was conducted in a diagnostic laboratory (Idexx Bioresearch, 
Ludwigsburg, Germany) using Helicobacter genus and Helicobacter species-specific PCR 
primers. 
 
 
Body weight and body composition 
 
Body weight was measured weekly from arrival at the facility until the end of the experiments. 
After sacrifice, 7 mice from each group were subjected to CT scanning (LaTheta LCT-100A 
scanner, Hitachi-Aloka Medical Ltd., Tokyo, Japan) for body composition, and the proportion 
between lean and fat mass (subcutaneous and intra-abdominal adipose tissue) in the region 
between lumbar vertebrae L1-L5 was analysed using LaTheta software (version 2.10, Hitachi- 
Aloka Medical Ltd.) [23, 24]. 
 
 
Feeding behavior 
 
After 6 weeks of HFHC diet feeding, R mice (n=8) and NR mice (n=8) were single-housed in 
BIODAQ cages (Research Diets, New Brunswick, NJ, USA) equipped with external food 
hoppers to measure food intake continuously. Meal size and meal pattern over 24h were then 
determined. Meal pattern data collected from each mouse were grouped into meals by 
clustering independent feeding bouts. A meal was defined as a minimum inter-meal interval 
(IMI) of 600 sec and minimum size of 0.02 g [25]. Mice were not disturbed during these 
measurements. 
The same mice were then transferred to an open-circuit indirect calorimetric system (TSE 
Phenomaster, TSE Systems GmbH, Bad Homburg, Germany) to monitor metabolic rate and 
respiratory gas exchange. Two weeks of adaptation were given prior to measurements for 
each test. 
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Glucose metabolism: oral glucose tolerance test and insulin sensitivity test 
 
Oral glucose tolerance (OGTT) and insulin sensitivity (IST) tests were carried out in separate 
groups of R mice and NR mice to avoid stress and excessive blood sampling. 
OGTTs were performed in R mice and NR mice on chow diet and after 1, 2 and 3 months of 
HFHC diet feeding (n=28 each time-point per group). Mice were fasted for 6h prior to the test 
and were briefly anesthetized with isoflurane (3% isoflurane in the induction chamber, 
0.8L/min) to collect blood in microvette EDTA microtubes (Sarstedt, Nümbrecht, Germany) by 
sublingual vein puncture to measure basal glucose and insulin levels. At T0, a baseline blood 
sample was collected and a bolus of glucose (2g/kg) was given by oral gavage, after which 
blood was sampled by tongue bleeding at time 15 and 30 min, and by tail bleeding at time 45, 
60, 90 and 120 min for glucose measurements (Breeze 2, Bayer Glucose Meter, Basel, 
Switzerland). The area under the curve (AUC) was calculated above the lowest glucose value 
of each mouse during the OGTT. Blood was kept on ice and centrifuged at 4°C for 5 min at 
11000 rpm. EDTA plasma was separated and stored at -80°C until assayed. Insulin levels at 
time-points 0, 15 and 30 min were measured with a specific Mouse Insulin ELISA (Mercodia 
AB, Uppsala, Sweden) (Data not shown). 
ISTs were performed using different cohorts of R mice (n=19) and NR mice (n=15), which 
were fasted for 4h and bled at the same time-points (see above). After baseline blood sample 
measurements, insulin Humalog (0.5U/kg, 100U.I./mL, Lilly, Geneva, Switzerland) was 
injected intraperitoneally and blood glucose levels were measured at 15, 30, 45, 60, 90 and 
120 min after injection in blood samples collected by tail bleeding. Mice that became 
hypoglycemic (i.e. reached glucose levels of 2.5 mmol/L or less) were immediately given a 
bolus of glucose (2g/kg) and were excluded from the test for all subsequent time-points. In our 
analysis particularly, 9/27 R mice and 8/23 NR mice were excluded. The AUC was calculated 
above the lowest level of glucose of each mouse during IST test. 
Cytokines and Transaminase measurements 
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Cytokines were measured in plasma isolated from terminal blood samples with V-Plex 
Cytokine kit (Meso Scale Discovery, Gaithersburg, MD, USA) following the manufacturer’s 
protocol. 
Plasma alanine transaminase (ALT) was measured via UniCel® DxC 800 Synchron® Clinical 
System in plasma of R mice and NR mice at the time of sacrifice, according to manufacturer’s 
instructions. 
 
 
Liver and pancreas histology 
 
All animals were deeply anesthetized by isoflurane and sacrificed via opening of the thoracic 
cavity and exsanguination by cardiac puncture. A complete necropsy, including a thorough 
external and internal gross post mortem examination was performed on each mouse. Mice 
were sacrificed at different time-points after 2, 3 and 4 months of HFHC diet feeding. Liver 
and pancreas were removed, weighed (liver) and appropriately sized samples were fixed in 
10% neutral-buffered formalin (Formafix, Hittnau, Switzerland) or snap frozen. Formalin-fixed 
samples were trimmed according to guidelines [26], dehydrated through graded alcohols and 
routinely paraffin wax embedded. Consecutive sections (3–5 µm) were prepared, mounted on 
glass slides and routinely stained with hematoxylin eosin (HE) or subjected to 
immunohistochemical staining. Microscopic findings in the HE-stained livers slides were 
classified with standard pathological nomenclature and severities of findings were graded on 
a scale of 0 to 4 (no finding present (0), minimal (Melander, #475), mild (2), moderate (3), or 
severe (4)). Grades of severity for microscopic findings were subjective; minimal was the least 
extent discernible and severe was the greatest extent possible [27]. Lesions that were not 
graded were marked as present. Nomenclature of the microscopic observations in the liver 
was consistent with INHAND published guides [28]. A silver stain was performed on the 
formalin-fixed paraffin-embedded liver sections of selected mice according to routine 
procedures to exclude the presence of argyrophilic bacteria. 
Immunohistochemistry  was  employed  on  liver  sections  from  selected  mice  for  the 
 
characterization of the inflammatory infiltrate and bile duct proliferation. Antibodies anti-CD3 
38  
(Clone SP7, Bioscience M3074, dilution 1:900), anti-CD45R/B220 (clone RA3-682, BD 
Pharmigen, dilution 1:800) and anti F4/80 (clone SP115, Invitrogen MA5-16363 dilution 1:150) 
were used for the characterization of T cells, B cells and macrophages, respectively. A pan 
cytokeratin antibody (clone PCK-26, Novus Biological, dilution 1:500) was employed for the 
identification of biliary duct epithelial cells. 
Oil red O (ORO) staining was performed on snap-frozen cryomold-embedded livers. Sections 
were cut at 6 μm, mounted on glass slides and allowed to dry at room temperature. They were 
then rinsed briefly in 50% ethanol, incubated in a 60% aqueous ORO solution (375.0 mg Oil 
Red O (Merck KGaA, Darmstadt, Germany) in isopropanol) at room temperature for 20 min, 
rinsed again in 50% ethanol and counterstained with hematoxylin for 2 min. ORO stained 
slides were scanned using a digital slide scanner (NanoZoomer-XR C12000, Hamamatsu 
Photonics K.K., Japan) and the fat content was calculated in the digital slides using the 
Visiopharm Integrator System (VIS, version 4.5.1.324, Visiopharm, Hørsholm, Denmark). 
Briefly, a threshold classification allowed recognition of positive (red) hepatocellular cytoplasm 
and negative hepatic parenchyma, and the results were expressed as positive area versus 
total area in the whole liver section. Data are presented as average (± SEM) percentage of 
lipid-containing parenchyma in the group. 
 
Triglycerides and non-esterified fatty acids in livers 
 
Approx. 50 mg of snap frozen liver were homogenized with 1 mL 2:1 chloroform:methanol 
(v/v) solution to measure triglyceride content. The homogenate was centrifuged for 5 min at 
2500 rpm and supernatant was collected and diluted with 0.9% NaCl. Samples were 
centrifuged for 5 min 2000 rpm, then resuspended in a 1:1 methanol:H2O (v/v) solution. The 
upper phase was then discarded, samples were let to dry and resuspended in Dimethyl 
sulfoxide (DMSO). Triglycerides content was then measured with the Cobas Mira Roche- 
Autoanalyzer (F. Hoffmann-La Roche Ltd., Basel, Switzerland), according to the 
manufacturer’s instructions. Non-esterified fatty acids (NEFA) were measured on approx. 10 
mg frozen liver following manufacturers’ procedure (Merck KGaA, Darmstadt, Germany). 
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Pancreatic islets isolation and glucose-stimulated insulin secretion 
 
At time of sacrifice, pancreas was digested and pancreatic islets were isolated using the 
adapted islets isolation procedure from Nordmann et al [29]. Subsequently, isolated islets 
were let recover for 2h in a cell culture incubator (37°C, 20%O2 and 5%CO2) and 10 islets/well 
were gently picked and plated into a 24 well ECM plate (Novamed, Jerusalem, Israel). Media 
was changed on day 2 and on day 4 when the glucose-stimulated insulin secretion (GSIS) 
test was performed following a procedure adapted from Rütti [30]. 
Krebs-Ringer phosphate solution supplemented with 0.1% BSA and 1M Hepes was prepared 
(KRH). Islets were pre-incubated for 30 min in KRH supplemented with 2.8 mM glucose at 
37°C to let islets adapt to KRH solution before collection of the supernatant to measure insulin 
secretion. To measure basal insulin release, islets were incubated for 1h with fresh KRH + 2.8 
mM glucose followed by 1h with KRH + 13.7 mM glucose to measure stimulated insulin 
release. After each incubation, supernatant was collected, immediately frozen and later used 
to measure secreted insulin. To quantify insulin content after the two incubations, islets were 
lysed with 0.18M HCl in 70% EtOH at 4°C overnight. Insulin was measured with the Mouse 
Insulin ELISA (Mercodia AB, Uppsala, Sweden) and secreted insulin was calculated as 
percentage of total insulin content. 
 
Lipid parameters 
 
Plasma total cholesterol and triglycerides were measured at TNO when mice were 6-7 weeks 
old to discriminate between R mice and NR mice. For consistency, we converted the unit for 
total cholesterol and triglyceride received from the TNO facility from mmol/L to mg/dL because 
all the measurements performed in our institute used this unit system. For our own 
measurements, an aliquot of blood collected from mice undergoing the IST was collected in 
Microvette Lithium-heparin vacutainers (Sarstedt, Nümbrecht, Germany) and used to analyze 
lipid parameters. An additional blood sample was collected at sacrifice by cardiac puncture. 
Blood was immediately centrifuged at 11000 rpm at 4°C for 5 min and heparin plasma was 
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aliquoted and stored at -80°C until assayed. Triglycerides, HDL-C and total cholesterol levels 
were analysed via UniCel® DxC 800 Synchron® Clinical System according to manufacturer’s 
instructions, measured in mg/dL. Non-esterified fatty acids (HR Series NEFA –HR, Wako, 
Virginia, USA) and beta-hydroxybutyrate (Randox D-3-Hydroxybutyrate, Randoy Laboratories 
Ltd., Crumlin, County Antrim, United Kingdom) were analysed in blood samples collected at 
sacrifice using a Cobas Mira Roche-Autoanalyzer (F. Hoffmann-La Roche Ltd., Basel, 
Switzerland), according to the manufacturer’s instructions. CETP activity was measured in 
plasma collected at sacrifice with CETP activity assay (CETP activity assay kit, MAK106, 
Merck KGaA, Darmstadt, Germany) according to manufacturer’s instructions. 
 
 
Bile acids profile in plasma and feces 
 
Samples were analysed by the Department of Laboratory Medicine, University of Groningen, 
using 25 µL of plasma and 50 mg of feces. For plasma samples, to each sample, 250 µL 
internal standard solution (0.1 µM D4-CA and DA-CDCA, 0.2 µM DA-TCA, DA-TCDCA, DA- 
GCA, D6-TDCA, D4-TUDCA, D4-Tb-MCA and D4-GCDCA) was added and vortexed. 
Samples were then centrifuged at 11000 rpm and the supernatant transferred into a clean 
glass tube. The liquid phase was then evaporated under nitrogen at 40°C. Before measuring, 
samples were reconstituted in 200 µL 1:1 methanol:H2O (v/v), vortexed for 60 sec and 
centrifuged for 3 min at 4000 rpm. The supernatant was transferred into a 0.2 µm spin-filter 
and centrifuged at 4200 rpm for 10 min. After filtering, the samples were analyzed (10 µL 
injection volume) by Nexera X2 Ultra High Performance Liquid Chromatography system 
(SHIMADZU, Kyoto, Japan), coupled to a SCIEX QTRAP 4500 MD triple quadrupole mass 
spectrometer (SCIEX, Framingham, MA, USA) (UHPLC-MS/MS) [22]. 
For feces samples, bile acid composition was determined by capillary gas chromatography on 
a Hewlett-Packard gas chromatograph (HP 6890) equipped with a FID and a CP Sil 19 
capillary column; length 25 m, internal diameter 250 µm and a film thickness of 0.2 µm 
(Chrompack BV, Middelburg, The Netherlands). Bile acids were methylated with a mixture of 
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methanol and acetyl chloride and trimethylsilylated with a mixture of piridyne, N,O-Bis 
(trimethylsilyl) trifluoroacetamide and trimethylchlorosilane. Neutral sterols were 
trimethylsilylated with a mixture of piridyne, N,O-Bis (trimethylsilyl) trifluoroacetamide and 
trimethylchlorosilane and measured on the same gas chromatograph equipped with the same 
column. 
 
 
Data Analysis and Statistics 
 
All data are expressed as mean ± standard error of the mean. Student’s T-test, 2 way-ANOVA 
followed by Tukey or Sidak post-hoc tests were used for comparison among the groups (NR 
mice vs R mice), as appropriate. For all statistical analysis, a p-value lower than 0.05 was 
considered significant. Data were analyzed using Prism GraphPad 8.0. 
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RESULTS 
 
Body weight, food intake, indirect calorimetry and body composition in R and NR mice 
Upon arrival in our facility on chow diet, R mice and NR mice did not show any differences in 
body weight. R mice gained significantly more body weight (initial body weight 31.2 ± 0.6 g 
and final body weight 49.7 ± 1.1 g) compared to NR mice (initial body weight 29.0 ± 0.4 g and 
final body weight 39.0 ± 0.9 g) after 16 weeks of HFHC diet feeding (Fig 1A). The difference 
in body weight was significant from the 2nd week of HFHC diet feeding. 
Body composition analysis showed no significant difference in lean mass (Fig 1F) and total fat 
mass between R mice and NR mice; nevertheless, NR mice had a tendency for decreased 
subcutaneous and significantly less intra-abdominal fat compared to R mice (Fig 1G). 
Ad libitum food intake over 24h (Fig 1B), number of meals per day (Fig 1C) and parameters 
of energy metabolism (respiratory exchange ratio (Fig 1D) and energy expenditure (Fig 1E)) 
revealed no difference between the two groups. 
 
 
Glucose and insulin tolerance in R mice and NR mice 
 
Oral glucose tolerance tests (OGTT) were performed at several time-points in mice on chow 
diet and after 1, 2 and 3 months of HFHC feeding diet, respectively (Fig 2A-D). Already when 
chow fed, R mice and NR mice displayed differences in their glucose metabolism (Fig 2A). 
Fasting (baseline) glucose levels were higher in R mice (10.4 ± 0.3 mmol/L) compared to NR 
mice (8.5 ± 0.3 mmol/L) and, with the exception of the 15 min time-point, this trend continued 
during the entire OGTT (Fig 2A). Although this difference at specific time-points, both groups 
were able to reach baseline values after 120 min of test, indicating similar glucose tolerance; 
even though AUC on chow diet of R mice was increased by 20% as compared to NR mice 
(Fig 2E), the difference did not reach significance. 
The difference between R mice and NR mice became more pronounced when mice were 
HFHC diet fed. Notably, after 1 month of HFHC diet feeding, R mice became glucose intolerant 
with higher glucose levels as compared to NR mice during the entire OGTT (Fig 2B). This 
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effect was exacerbated after 2 and 3 months of HFHC diet feeding (Fig 2C-D). After 3 months 
of HFHC diet, NR mice also slightly increased their glucose levels probably due to aging and 
the consequences of HFHC diet feeding [31]. This was also reflected in the higher AUC (Fig 
2E) compared to earlier time-points. 
 
 
Insulin sensitivity tests (IST) were performed in different groups of mice at the same time-point 
as the OGTT (Fig 3A-D). R mice, as previously observed during the OGTT, displayed higher 
glucose level at times 0 and 15 compared to NR mice. Already on chow diet (Fig 3A), and 
after 1 month of HFHC diet feeding (Fig 3B), NR mice showed a better insulin sensitivity 
response compared to R mice (indicated by the higher AUC in NR mice; Fig 3E). Over time, 
the differences between the two groups decreased probably due to aging effect, without 
reaching significance in the AUC (Fig 3E). Thus, even though R mice display higher glucose 
values during the IST, which indicates reduced glucose tolerance, on HFHC diet, based on 
the AUC during the IST, their overall insulin sensitivity was similar to NR mice (Fig 3E). 
 
 
Morphology and lipid profile in the liver of R mice and NR mice 
 
There was no gross abnormality detected in livers of R mice euthanized at approximately 14- 
 
16 weeks of age and kept on the chow diet, whilst livers of NR mice under the same 
experimental conditions appeared firmer than normal and exhibited a rough granular surface 
with multiple minimal indentations. Livers of 20-34 weeks old R mice fed the HFHC diet for 2, 
3 or 4 months, respectively, were mildly enlarged, with rounded borders, and exhibited a 
diffuse yellow-brown discoloration and a homogeneously smooth surface (Fig 4A). Age- 
matched NR mice receiving the HFHC diet presented small, firm livers, with an extremely 
irregular granular surface, along with rare (3/30 NR mice) multifocal nodular masses, 0.1-0.4 
cm in diameter (Fig 4B). 
In line with these macroscopic observations, there was a statistically significant decrease in 
mean absolute liver weights in 20-34 weeks old, HFHC diet fed NR mice when compared to 
R mice under the same experimental conditions (1.8 ± 0.2 vs 2.9 ± 0.3 g; p < 0.01) (Fig 4I). 
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The results of the histopathological analysis are presented in Table 2. Apart from the presence 
of variably sized, predominantly periportal cytoplasmic eosinophilic inclusions (up to 20 µm in 
diameter) within the hepatocytes, indicative of mutant Apo-E lipoprotein accumulation [32], no 
histological abnormality was observed in the liver of R mice (5/5) fed the chow diet (Fig 4C). 
In contrast, NR mice (5/5) exhibited a minimal inflammatory response, alongside a slightly 
increased severity of eosinophilic droplets (average severity 3.3 ± 0.3 in R mice vs 4.0 ± 0 in 
NR mice). Inflammation was characterized by scattered, predominantly periportal foci of 
lymphocytes, macrophages and neutrophils, associated with minimal bile duct proliferation 
(Fig 4D, Table 2). 
After HFHC diet feeding, mice from both groups exhibited minimal to severe macro- and micro- 
vesicular lipidosis (Fig 4E-F, Table 2), which progressively increased in severity with time 
(Table 1S). Lipidosis was mainly microvesicular in R mice and occurred with a higher average 
severity (3.3 ± 0.2) compared to NR mice (1.8 ± 0.2), in which a macrovacuolar pattern was 
noted more often. Histomorphometrical analysis of lipid droplets in liver sections stained with 
ORO confirmed this result, with livers of R mice showing higher proportions of fat content vs 
total parenchyma (76.6%) compared to NR mice livers (53.1%) (Fig 4E-F inset). The higher 
grade of hepatic lipidosis correlated with increased triglycerides levels (1.5 ± 0.1 mg/dL/g vs 
2.7 ± 0.1 mg/dL/g) and non-esterified fatty acids (45.5 ± 3.6 mmol/L/g vs 49.9 ± 5.1 mmol/L/g) 
in livers of R mice vs NR mice (Fig 4G-H). 
Chronic inflammation occurred with higher incidence and severity in NR mice compared to R 
mice (Table 2, Fig 5A-L). In the latter, the inflammatory reaction consisted of scattered 
aggregates of lymphocytes and macrophages, clustering within or at the periphery of lipidotic 
areas, associated with minimal bile duct proliferation (Fig 5A and 5C-F). The liver of NR mice 
showed, instead, a prominent mixed inflammatory cell infiltration expanding and bridging 
portal areas, dominated by T and B cells and macrophages, along with fewer plasma cell and 
neutrophils (Fig 5B and 5G-I). Chronic inflammation was accompanied by minimal fibrosis and 
prominent bile duct hyperplasia (Fig 5B and 5G-J). A few (3/30) NR mice exhibited proliferative 
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preneoplastic lesions, such as eosinophilic and clear cell foci of hepatocellular alteration (1/30, 
Fig 5K) and hepatocellular adenomas (2/30, Fig 5L), which correlated with the nodular masses 
observed macroscopically. There was no evidence of hepatocellular proliferative lesions in R 
mice. 
Cytoplasmic eosinophilic inclusions occurred with lower severity in mice fed with the HFHC 
diet, compared to mice given a chow diet. This might be due to aging or to the concurrent high 
degree of lipidosis, which somehow prevents the formation or detection of these structures. 
However, similarly to mice fed with the chow diet, eosinophilic inclusions were observed with 
increased severity in NR mice (2.0 ± 0.3) compared to R mice (0.8 ± 0.2). 
Thus, we observed two distinct phenotypes under HFHC diet feeding conditions. R mice 
showed increased lipidosis (mainly microlipidosis) along with mild inflammation, while NR 
mice showed lower lipidosis levels (mainly macrolipidosis) but higher incidence and severity 
of chronic inflammation; in a few NR mice, we also found evidence of hepatocellular 
proliferative lesions. 
 
 
Pancreas 
 
To further understand the regulation of glucose metabolism in R mice versus NR mice, 
pancreas histological analysis was performed; no histological abnormalities were found in R 
mice and NR mice (data not shown). These results agree with our findings obtained following 
static glucose stimulation in isolated islets from R mice and NR mice. In fact, static high 
glucose stimulation (13.7 mM) induced a similar increase in insulin secretion in pancreatic 
islets isolated from R mice and NR mice (Fig 6). 
 
 
 
 
 
Cytokines and Transaminase in circulating blood of R mice and NR mice 
 
Plasma cytokines concentrations were similar between R mice and NR mice at time of 
sacrifice, i.e. after 3 months of HFHC feeding (Fig 7). 
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However, increased levels of alanine transaminase (ALT) were observed in NR mice after 3 
months of HFHC diet compared to chow conditions and compared to R mice at the same time- 
point (Fig 4J). This confirms liver damage as shown from histology of NR mice. 
 
 
Lipid metabolism in R mice and NR mice 
 
At the age of 6-7 weeks old, at TNO mice were tested for total cholesterol and triglycerides 
plasma levels to discriminate between R mice and NR mice. As expected, R mice displayed 
higher plasma cholesterol (2.9 ± 0.1 mmol/L; i.e.113.2 ± 3.8 mg/dL) compared to NR mice (1.7 
± 0.0 mmol/L; i.e. 68.4 ± 1.9 mg/dL) (Fig 8A). 
 
Plasma total cholesterol was measured again upon arrival at our facility on chow diet, and 
after 1, 2 and 3 months of HFHC diet. Particularly during the first 2 months on HFHC diet, R 
mice had significantly increased plasma total cholesterol whereas cholesterol levels in NR 
mice remained similar to the chow-feeding period (Fig 8B). However, after 3 months of HFHC 
diet, NR mice showed significantly higher values (81.6 ± 3.8 mg/dL) in total cholesterol 
compared to chow (34.4 ± 2.9 mg/dL) (Fig 8B). 
Triglycerides plasma levels were higher in R mice (3.9 ± 0.2 mmol/L; i.e. 341.5 ± 13.7 mg/dL) 
vs NR mice (0.9 ± 0.0 mmol/L; i.e. 79.4 ± 2.4 mg/mL) at the age of 6-7 weeks old, when 
measured at TNO (Fig 8C). Similar to total cholesterol, HFHC diet feeding resulted in 
significantly higher triglycerides concentrations in R mice than in NR mice (Fig 8D). R mice 
fed the HFHC diet showed uniformly high HDL-cholesterol (HDL-C) level, regardless of the 
duration of HFHC feeding (Fig 8F). 
Free fatty acids (P<0.05, Fig 8G) were also significantly increased after 3 months of HFHC 
diet. No difference was noticed in beta-hydroxybutyrate levels between NR mice and R mice 
(Fig 8H). 
At time of sacrifice, CETP activity, the enzyme that facilitates the transport of cholesterol ester 
and triglycerides between lipoproteins, was slightly higher in NR mice compared to R mice 
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(4704 ± 324 pmol transferred vs 3488 ± 537 pmol transferred), but the difference was not 
significant (Fig 8E). 
Together, these results demonstrate that the lipid profile in R mice is markedly altered 
compared to NR mice kept under a HFHC diet feeding regimen. 
 
 
Bile acid profile in plasma and feces 
 
Plasma levels of bile acids were investigated at time of sacrifice (Fig 9). Overall, R mice 
showed decreased total bile concentrations; particularly, among free bile acids, cholic acid 
(CA), deoxycholic acid (DCA), and b-muricholic acid (b-MCA) compared to NR mice (Fig 9). 
All taurine-conjugated bile acids were also lower in NR mice compared to R mice (Fig 9). Fecal 
coprostanol excretion was higher in R mice compared to NR mice (Fig 10A). No other 
differences were found in excreted bile acids between R mice and NR mice (Fig10 B-J). 
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Discussion 
 
This study aimed to characterize the long-term effect of a 60% kcal fat diet supplemented with 
0.25% cholesterol (HFHC) diet on various parameters linked to glucose and lipid metabolism 
in ApoE3L.CETP mice, a humanized mouse model for the metabolic syndrome (Speliotes, 
#1157) [20]. The mutation ApoE3Leiden [18, 19] and the human transgene CETP gene [19] 
enable these mice' lipid metabolism and profile to be more similar to humans, hence they are 
one of the best animal models available to assess alterations in lipid metabolism in response 
to HFHC diet [19, 20]. 
 
 
ApoE3L.CETP mice exhibit a dyslipidemic phenotype combined with obesity, insulin 
resistance and atherosclerosis when administered HFHC diet [33-36]. Interestingly, some 
degree of phenotypic heterogeneity has been reported among age-matched individuals kept 
under similar experimental conditions [22]. Mice that do not fully display the expected 
phenotype, i.e., increased body weight and increased triglycerides and total cholesterol levels 
after HFHC diet exposure, are classified as non-responders (NR) and represent approximately 
20% of the total ApoE3L.CETP mice population at TNO (TNO innovation for life, Leiden, The 
Netherlands; personal communication), the facility that established this mouse model and 
supplied them for this current study. In fact, NR mice and R mice can already be differentiated 
at young age when chow fed, based on their prevailing triglyceride and cholesterol plasma 
levels. 
 
 
To our knowledge, the reasons for these phenotypic differences between R mice and NR mice 
have never been addressed in detail and it is not clear why APOE3L.CETP mice sharing the 
same genetic background exhibit heterogeneous responses to HFHC diet. We therefore 
believe that deciphering the metabolic differences found between R mice and NR mice is 
important. In addition, in some previous published studies, it is not explicitly mentioned 
whether NR mice were included [20, 22, 37]. This warrants overall caution when evaluating 
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heterogeneous metabolic profiles and responses in ApoE3L.CETP mice that might be related 
to the dimorphic phenotype of R mice and NR mice [22]. 
To assess the heterogeneity of the ApoE3L.CETP mice responses and to test the suitability 
of these mice to study the MetS [22], we investigated in detail body weight gain, feeding 
behavior, glucose metabolism, lipid profile, liver histology and inflammation markers over time 
in several cohorts of mice, and compared mice that were classified as young animals as R 
mice to mice that were classified as NR mice. 
In line with what has been previously observed [22], our results confirmed a sharp distinction 
between R mice and NR mice responses to a HFHC diet. Mice originally classified as R mice 
were more prone to display the features of the MetS, and exhibited increased body weight, 
increased subcutaneous and intra-abdominal adipose tissues, increased plasma total 
cholesterol, triglycerides and HDL-C [19, 20, 22, 37], and reduced glucose sensitivity [38, 39] 
compared to NR mice. 
 
 
In line with lipid metabolism parameters, histological analysis showed that hepatocellular 
lipidosis in R mice administered HFHC diet for 2, 3 or 4 months occurred with a high severity 
progressing over time (average severity: 3.3 ± 0.2, corresponding to 76.6% lipid content in the 
ORO stained liver sections), whilst NR mice exhibited reduced levels of lipidosis (average 
severity: 1.8 ± 0.2, corresponding to 53.1% lipid content in the ORO stained liver sections). 
Surprisingly, however, NR mice showed prominent hepatic inflammatory and proliferative 
changes, characterized by severe diffuse chronic lymphohistiocytic infiltration, bile duct 
proliferation, occasional foci of hepatocellular alteration, and hepatic adenomas. R mice, in 
contrast, exhibited only minimal inflammation and bile duct proliferation, in the absence of 
preneoplastic or neoplastic lesions. On an individual basis, there was a clear inverse 
correlation between the severity of chronic inflammation, and hepatocellular lipidosis, with 
mice that had high inflammatory scores showing low accumulation of hepatic lipids and 
decreased body weights, and vice-versa. This indicates that the hepatic pathology seen in NR 
mice may have a detrimental effect on hepatic function, as indicated by decreased lipid 
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accumulation - which we interpret as an inability to properly metabolize fat - and increased 
levels of ALT. 
Differences in liver histology between R mice and NR mice were prominent following 2-4 
months of HFHC diet feeding, however minimal inflammatory changes were already observed 
in NR mice at an earlier age (12-16 weeks) while kept on chow diet. Age-matched R mice kept 
under the same experimental conditions had no histological abnormality in the liver. 
 
 
High body weight, high cholesterol and triglycerides levels and a liver histology dominated by 
lipidosis accompanied by minimal inflammatory changes are therefore the salient features of 
a responsive R phenotype. Based on this definition, separation between R mice and NR mice 
at an early stage based on triglycerides levels (<2mmol/L, i.e., 177 mg/mL) seems to be 
generally predictive of the final phenotype. However, we noted a certain degree of 
heterogeneity also within NR and R mice, respectively, leading to a partial overlap between 
the two groups. There were indeed a few mice within each cohort that did not show the 
predicted phenotype. 2/32 R mice (6.2%) were considered as outliers, i.e. mice originally 
classified as responders which exhibited low body weight (28.3 g and 35 g), low lipidosis 
(mainly macrolipidosis: scored 2 or 3) and high levels of chronic inflammation (scored 4). In 
the NR cohort, 3/30 mice (10%) exhibited parameters consistent with a responder mouse, with 
higher body weight gain (40, 49 and 51 g), high lipidosis (mainly microlipidosis: scored 4) and 
low levels of chronic inflammation (scored 0 or 1). 
We suggest, therefore, that the introduction of other parameters such as liver histology might 
 
be helpful for the final classification of mice. It is important to note that a heterogeneity in the 
response to HFHC diet is also observed in humans with dysregulated metabolism, and it had 
to be taken in to account when transferring knowledge from an animal model to humans [20, 
40]. 
In our study, we maintained the arbitrary classification carried out based only on cholesterol 
and triglycerides, given that the pathophysiological mechanisms underlying the NR phenotype 
are unknown and might have a multifactorial origin. Lack of the expected response might be 
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related to the C57BL/6J strain background, as it has been previously shown by Burcelin et al 
 
[41] and Hull et al [42]. In these studies, it was reported that C57BL/6J mice do not respond 
uniformly to HFHC diet feeding. Indeed, some mice gained weight, developed obesity and 
glucose intolerance, while some others did not [38, 39, 43-45]. The reason for this different 
response usually remain unclear. 
 
 
We originally hypothesized that the difference between R mice and NR mice might be due to 
different copy numbers of the CETP transgene or to altered transgene expression. While we 
did not directly measure copy numbers of the CETP transgene in NR mice and R mice, this 
seems to be unlikely based on our results, as the measured CETP activity did not differ 
between NR mice and R mice. 
 
 
It has been previously reported that APOE3Leiden gene overexpressing strains exhibit typical 
round cytoplasmic eosinophilic droplets, predominantly in the periportal hepatocytes [32]. 
These characteristic inclusions are consistent with aggregates of ApoE3Leiden, however the 
mechanisms which lead to their accumulation are still poorly understood. We noted that NR 
mice fed with a chow diet had higher numbers of cytoplasmic inclusions compared to R mice. 
This difference appeared more evident following HFHC diet feeding. A possible explanation 
might be that excessive accumulation of ApoE3Leiden protein elicits some form of damage, 
followed by an inflammatory response; however considerably more work will need to be done 
to elucidate a possible link between the presence of ApoE3Leiden and a NR phenotype. 
 
 
Chronic-active inflammation, associated with cholangitis, biliary hyperplasia and proliferative 
hepatocellular lesions has been described in the liver of mice following chronic infection by 
Helicobacter hepaticus [28, 46]. Whilst most animals that carry Helicobacter spp. are 
asymptomatic, susceptible strains and individual mice might manifest clinical signs and lesions 
and we questioned whether the NR mouse phenotype could be simply the expression of an 
environmental infection in a proportion of more susceptible mice. FELASA-accredited health 
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check analyses that were conducted at the originating facility, as well as at our premises, 
revealed that the cohorts of mice employed in the current study did not carry pathogenic 
etiologic agents. There was no evidence of bacterial organisms in the livers of selected NR 
mice subjected to a silver stain for the detection of argyrophilic bacteria such as Helicobacter 
spp. Absence of Helicobacter was further confirmed by a qPCR analysis conducted on a 
pooled liver specimen obtained from R mice and NR mice. 
 
 
Since R mice and NR mice did not show any differences in daily food intake or in their feeding 
behavior, the fact that NR mice did not increase their body weight as much as R mice cannot 
be explained by a diet-related aspect or a decrease in food intake. Interestingly, energy 
expenditure also did not differ between R and NR mice but we did not quantify total caloric 
loss via the feces as a possible mechanism. 
 
 
Moreover, glucose metabolism was different between R mice and NR mice, and the difference 
was more prominent on HFHC diet feeding condition. Particularly, when HFHC diet fed, R 
mice showed increased basal blood glucose compared to NR mice suggesting that HFHC diet 
alters the basal glucose metabolism in R mice, and to a lesser extent in NR mice; this is in line 
with previously published studies [47]. We noticed a tendency toward glucose intolerance in 
R mice similarly to what reported in previous studies conducted with C57BL/6J that also show 
an increase in basal blood glucose values after HFHC diet [38, 44, 45, 48, 49]. Even though 
NR mice showed better glucose tolerance and insulin sensitivity during OGTT and IST, their 
basal values also slightly increased over time as a potential consequence of HFHC diet and 
aging [50]. 
We did not find major histological abnormalities in the pancreas of R mice that might explain 
the difference in glucose tolerance. Moreover, insulin secretion after glucose stimulation in 
islets isolated from R mice and NR mice did not show any differences. This indicates that 
insulin sensitivity rather than insulin secretion may be more critical for the different glucose 
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tolerance observed in R mice compared to NR mice. We did not perform a hyperinsulinemic 
euglycemic clamp to investigate the animals' insulin sensitivity in detail. 
 
 
Studies in humans [51] and animal models showed the increasing importance of bile acids in 
modulating body glucose, lipid metabolism and body weight [52]. Our findings are contrary 
from previous data employing the same mouse model [22]: surprisingly our results show 
decreased levels of most of the circulating bile acids (CA, DCA, TDCA, TCDCA, TUDCA, 
TA/TB-MCA) in R mice compared to NR mice. We hypothesized that these differences in bile 
acids between R mice and NR mice are due to a dysregulation of bile acids metabolism: in 
fact, because of the severe liver pathology affecting NR mice, NR mice might be unable to 
reabsorb and recycle bile acids via hepatic portal vein circulation, hence bile acids might tend 
to accumulate in the systemic circulation, potentially explaining higher bile acids values in NR 
mice compared to R mice [53]. 
Indeed, some studies using another mouse model had shown how increased levels of MCA, 
as seen in our NR mice, might protect against body weight gain, steatosis, 
hypercholesterolemia and insulin resistance [54]. Higher CA levels in NR coupled with lower 
hepatic TG levels confirmed also previous data [55]. Furthermore, different metabolism of bile 
acids by gut microbiota may also explain why R mice and NR mice might show differences in 
their bile acids profile [56] but this was not formally tested in our studies. 
 
Another aspect to take into consideration is that obesity is often accompanied by an increase 
in the inflammatory status in mice [44] and humans [57-59]. Our data indicate that circulating 
cytokines did not differ between R mice and NR mice; hence, the inflammation observed in 
livers of NR mice appears to be organ specific rather than a systemic feature of NR mice 
compared to R mice [44]. 
 
 
In summary, our findings suggest that in the heterogeneity previously described for the 
ApoE3L.CETP mice, two different and distinct phenotypes need to be considered: R mice and 
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NR mice. Particularly, R mice showed the expected phenotype after HFHC diet feeding, 
confirming its use as a good mouse model to describe the MetS especially in relation to lipid 
metabolism. 
With respect to the liver histological finding, the histological features recapitulate those seen 
in NAFLD and likely shares the same pathophysiological mechanisms seen in R mice. As 
shown by Lau et al [60] several mice models were used to investigate NAFLD as C57BL/6, 
db/db and ob/ob mice. Nevertheless, we would rather consider the use of C57BL/6 mice as 
more accurate model for NAFLD [61, 62], since ApoE3L.CETP mice showed other liver 
histological features (i.e. minimal bile duct proliferation) that can create confounding factors. 
On the other hand, NR mice do not show the expected phenotype after HFHC diet feeding, 
investigations into liver morphology and function indicated that NR mice rather than the R mice 
might suffer from a severely disturbed liver metabolism. The fact that NR mice do not 
"respond" to the HFHC diet may therefore indicate that these animals may not be protected 
from the development of diet-induced obesity (and its consequences) in the classical sense, 
but that the NR mice may in fact be unable to respond adequately to the HFHC diet because 
of compromised liver function. For this reason, the liver pathology in NR mice would rather be 
classified as nonalcoholic steatohepatitis (Smolen, #235), i.e. a more aggressive phenotype 
of NAFLD [63]. 
We therefore suggest using NR mice with caution; it may be safer to use only R mice in 
 
experimental settings and to compare them to appropriate controls within the R cohorts, rather 
than taking NR mice as control groups. It may also be advised to reclassify the mice based on 
the post mortem examination and clinical chemistry analysis, to confirm their R mice 
phenotype based on liver histology and function, respectively. 
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Table 1: Experimental design 
 
Mice experimental design                       
  TNO facility Zürich facility 
   adaptation                     
   chow diet high fat high cholesterol diet 
 weeks  -1 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
 mice age 6-7 wks 7-19 wks                      
 
1st cohort 
mice 
group 1 TC/TG   OGTT    OGTT    OGTT    OGTT       sacrifice/islets 
group 2 TC/TG 
  IST    IST    IST    IST       
sacrifice/islets 
blood blood blood blood 
  8-14 wks                      
 
2nd cohort 
mice 
group 1 TC/TG   OGTT    OGTT    OGTT    OGTT     sacrifice/islets 
group 2 TC/TG 
  IST    IST    IST    IST  
sacrifice/islets 
   
blood blood blood blood 
group 3 TC/TG        BioDAQ TSE system sacrifice/histology       
                         
TC: total cholesterol                        
TG: triglycerides                        
NEFA: non-esterified fatty acids                       
BHB: betahydroxybutyrate                       
OGTT: oral glucose tolerance test                       
IST: insulin sensitivity test                        
HDL-C: high.density lipoprotein                       
ALT: alanine aminotransferase                       
                         
                         
blood: TC, TG, HDL-C time-point measurements                     
sacrifice terminal blood collection, NEFA, BHB, cytokines, ALT                    
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 Table 2. Liver scores for NAFLD 
 
Chow diet HFHC diet 
 
R NR R NR 
Age mice (weeks) 12-16 12-16 28-34 28-34 
Livera 5 5 32 30 
Hepatocellular Lipidosisb 0/5 0/5 32/32 30/30 
Grade 0 5 5 0 0 
Grade 1 0 0 4 9 
Grade 2 0 0 1 15 
Grade 3 0 0 8 5 
Grade 4 0 0 19 1 
Average severityc 0 ± 0 0 ± 0 3.3 ± 0.2 1.7 ± 0.2*** 
Chronic Inflammationb 0/5 5/5 14/32 28/30 
Grade 0 5 0 18 2 
Grade 1 0 5 13 0 
Grade 2 0 0 1 3 
Grade 3 0 0 0 12 
Grade 4 0 0 0 13 
Average severityc 0 ± 0 1± 0 0.5 ± 0.1 3.2 ± 0.4*** 
Hepatocellular Eosinophilic Cytoplasmic 
Inclusionsb 
5/5 5/5 19/32 28/30 
Grade 0 0 0 13 2 
Grade 1 0 0 12 5 
Grade 2 1 0 7 14 
Grade 3 3 0 0 9 
Grade 4 1 5 0 0 
Average severityc 3 ± 0.3 4 ± 0 0.8 ± 0.2 2.0 ± 0.3 
Isolated Focib 0/5 0/5 0/32 1/30 
Adenomasb 0/5 0/5 0/32 2/30 
a: number of liver samples analysed, b: incidence of the findings, c: Average severity calculated 
as sum of all the scores given divided by the total number of liver samples analysed 
***: p<0.001, NR v R, resp., Unpaired Student’s T test 
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Figures legend 
 
Fig 1: (A) Body weight over a 16-weeks period on HFHC diet in responders (R mice, n=51) 
and non-responders (NR mice, n=52) ApoE3L.CETP male mice; R mice increased body 
weight more compared to NR mice with HFHC diet feeding. (B) average 24h food intake and 
(C) average number of meal bouts in 24h after 8 weeks on HFHC diet in R mice (n=8) and NR 
mice (n=8); mice displayed no differences between the two groups. (D) Respiratory Exchange 
Ratio and (E) Energy Expenditure in R mice (n=8) and NR mice (n= 8) mice after 10 weeks 
on HFHC diet; no significant differences were found. (F) Lean and fat mass did not differ 
between R mice (n=7) and NR mice (n=7). (G) Subcutaneous and intra-abdominal fat mass 
revealed increased intra-abdominal fat mass in R mice. Data are represented as mean ± SEM. 
*, *** P< 0.05 or 0.001, resp., NR vs. R, after post hoc Sidak adjustment significant intergroup 
differences were found by 2-way ANOVA multiple comparison (A, D, E) or unpaired Student’s 
T test, (B, C, F, G). 
 
 
Fig 2: Oral glucose tolerance test was performed in responder mice (R mice = 28) and non- 
responders (NR mice =28) mice on chow (A), and after 1 (B), 2 (C) and 3 (D) months of HFHC 
diet. R mice from 1 month of HFHC diet displayed glucose intolerance compared to NR mice. 
(E) Area under the curve (AUC) over 120 min was calculated during the OGTT, above the 
lowest glucose value of each respective animal. Data represented as mean ± SEM., *, **, *** 
P < 0.05, 0.01, or 0.001 NR vs. R, resp., after unpaired Student’s T test (Veitenhansl, #514) 
or after post hoc Sidak adjustment significant intergroup differences were found by 2-way 
ANOVA multiple comparison (E); different letters indicate significant differences. 
 
 
Fig 3: Insulin sensitivity test was performed in responder mice (R mice = 19) and non- 
responder mice (NR mice = 15) on chow (A), and after 1 (B), 2 (C) and 3 (D) months of HFHC 
diet. At each time-point R mice displayed lower insulin sensitivity compared to NR mice. (E) 
Area under the curve (AUC) over 120 min was calculated during IST above the lowest glucose 
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value during the test. Data represented as mean ± SEM., *, **, *** P< 0.05, 0.01 or 0.001 NR 
vs. R, resp., after unpaired Student’s T test (Veitenhansl, #514) or after post hoc Sidak 
adjustment significant intergroup differences were found by 2-way ANOVA multiple 
comparison (E). Different letters indicate significant differences. 
 
 
Fig 4: (A and B) microphotographs of livers from R mouse (A) and NR mouse (B) after 3 
months-HFHC diet. (A) R mouse liver show diffuse light brown discoloration, consistent with 
mild lipidosis. (B) NR mouse liver show multifocal well demarcated nodular masses (arrows; 
hepatocellular adenoma). (C and D) HE-stained liver sections from NR and R mice on a chow 
diet, scale bars = 100 µm: (C) Presence of eosinophilic cytoplasmic droplets (arrowheads), in 
a R mouse, (D) Minimal chronic inflammation (arrow) in a NR mouse. Eosinophilic droplets 
are increased in number compared to C. (E-F) HE-stained liver sections from mice on a HFHC 
diet, scale bars = 100 µm. Insets: Oil red O (ORO) stained liver sections from the same mice, 
scale bars = 20 µm: (E) R mouse: severe, predominantly microvesicular lipidosis (*). Inset: a 
high proportion of the hepatocyte cytoplasm contains ORO-positive lipid droplets. (F) NR 
mouse: mild, predominantly macrovesicular lipidosis (*). Inset: ORO-positive lipid content 
within the hepatocytes is decreased compared to E. (G) triglycerides levels extracted from 
livers from NR mice (n=10) and R mice (n=10) after sacrifice and (H) liver non-esterified fatty 
acids in NR mice (n=17) and R mice (n=15). (I) Absolute liver weight in R and NR mice on 2, 
3 and 4 months ofHFHC diet. (J) Alanine transaminase (ALT) plasma levels in R mice (n=7) 
and NR mice (n=9) chow fed and after 3 months of HFHC diet. Data are represented as mean 
± SEM. *, *** P<0.05 or 0.001, NR vs. R, resp., after unpaired Student’s T test (G-H) or after 
 
post hoc Sidak adjustment significant intergroup differences were found by 2-way ANOVA 
multiple comparison (I and J); different letters indicate significant differences. 
 
 
Fig 5: (A - B) HE-stained liver sections from mice fed HFHC diet, scale bars = 100 µm. (A) R 
mouse. Minimal chronic inflammation, characterized by scattered inflammatory cells (green 
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arrowhead) and negligible bile duct proliferation (arrow). Moderate numbers of eosinophilic 
cytoplasmic droplets (black arrowhead) are detected. (B) NR mouse. Marked chronic 
inflammatory reaction, with mononuclear cell infiltration (black arrowhead) and prominent bile 
duct proliferation (green arrowhead). Eosinophilic droplets (black arrowheads) are increased 
in number compared to R mouse. (Stemberger-Papic, #159;Veitenhansl, #514) Liver 
sections from a R mouse (Stemberger-Papic, #159) and a NR mouse (Veitenhansl, #514) 
on a HFHC diet, subjected to immunohistochemistry against the CD3 (T lymphocytes, C/G), 
CD45R/B220 (B lymphocytes, D/H), F4/80 (macrophages, E/I) and cytokeratin (biliary ductal 
epithelial cells, F/J) antigens, scale bars = 50 µm. Microphotographs are taken from the same 
area depicted in A or B, respectivey, (K and L) HE-stained liver sections from NR mice on a 
high fat high cholesterol (HFHC) diet. (K) Focus of cellular alteration (arrowheads), scale bar 
= 500 µm. Insets: Higher magnification of the lesion, scale bar = 50 µm. (L) Hepatocellular 
 
adenoma (arrowheads), scale bar = 1 mm. 
 
 
 
Fig 6: Insulin secretion expressed as a percentage of total insulin content after glucose 
stimulated insulin secretion test (GSIS) in islets isolated from NR mice and R mice and 
cultured for 4 days. Data are represented as mean ± SEM. *, P< 0.05, resp., NR vs. R, after 
post hoc Tukey adjustment significant intergroup differences were found by 2-way ANOVA 
multiple comparison. 
 
 
Fig 7: Plasma cytokines in plasma from non-responder (NR mice, n=7) and responder (R mice, 
n=9) mice at the time of sacrifice: (A) Interferon- g, IFN-g. (B) Interleukin 10, IL-10. (C) 
Interleukin 12p70, IL-12p70. (D) Interleukin 1b, IL-1b. (E) Interleukin 2, IL-2. (F) Interleukin 4, 
IL-4. (G) Interleukin 5, IL-5. (H) Interleukin 6, IL-6. (I) Keratinocyte chemoattractant/growth- 
regulated oncogene, KC-GRO and (J) tumour necrosis factor a, TNF-a. No difference 
between the two groups was found. Data are represented as mean ± SEM. *, P< 0.05, NR vs. 
R, resp after unpaired Student’s T test. 
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Fig 8: Plasma lipid profile in non-responder (NR mice, n=11) and responder (R mice, n=13) 
mice at different time points. Total cholesterol (A, B) and triglycerides (C, D) at aged 6-7 
weeks, analysis performed from TNO when discrimination between R mice and NR mice took 
place (A, C) and at time 0 (chow fed upon arrival in our facility), and after 1, 2 and 3 months 
of HFHC diet (B, D). (E) CETP activity at time of sacrifice in NR mice (n=10) and R mice (n=8); 
no difference was found. (F) HDL cholesterol (HDL-C) on chow diet upon arrival, and after 1, 
2 and 3 months of HFHC. (G) non-esterified fatty acids (NEFA) were higher in R mice vs NR 
mice, and (H) and beta-hydroxybutyrate (BHB) in NR mice (n=10) and R mice (n=10). Data 
are represented as mean ± SEM. *, *** P< 0.05 or 0.001, resp., NR vs. R, after post hoc Tukey 
adjustment significant intergroup differences were found by 2-way ANOVA multiple 
comparison (B, D, F) or unpaired Student’s T test, (A, C, E, G, H). Different letters indicate 
significant differences 
 
 
Fig 9: Total plasma bile acids profile in non-responder (NR) and responder (R) mice at time of 
sacrifice. (A) Total bile acids, total BA (n=17, 20). (B) cholic acid, CA (n=14, 15). (C) 
chenodeoxycholic acid, CDCA (n=14, 10). (D) deoxycholic acid, DCA (n=17, 15). (E) a- 
muricholic acid, a -MCA (n=13, 6). (F) b-muricholic acid, b-MCA (n=15, 14). (G) tauro cholic 
acids, TCA levels (n=15, 15). (H) taurodeoxycholic acid, TDCA (n=17, 15). (I) taurocheno 
deoxycholic acid, TCDCA (n=16,10), (J) tauroursodeoxycholic acid, TUDCA (n=17, 20), (K) 
tauro-α-muricholic acid, Tα-MCA (n=16, 14) and (L) tauro-b-muricholic acid, Tb-MCA (n=17, 
12). Data are represented as mean ± SEM. *, **, *** P< 0.05, 0.01 or 0.001, resp., NR vs. R, 
using unpaired Student’s T test. 
 
Fig  10:  Total  coprostanol,  cholesterol,  dihydrocholesterol  and  bile  acids  profile  in non- 
responder (NR) and responder (R) mice feces at time of sacrifice. (A) Coprostanol, Copr (n=5, 
2). (B) cholesterol, Chol (n=6, 5). (C) dihydrocholestero,l diHyChol (n=5, 5). (D) cholic acid, 
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CA (n=6, 5). (E) allo cholic acid, alloCA (n=6, 5). (F) deoxy cholic acid, DCA (n=6, 5). (G) a- 
muricholic acid, a -MCA (n=6, 5). (H) b-muricholic acid, b-MCA (n= 6, 5). (I) w-muricholic acid, 
w-MCA (n= 6, 5). (J) total bile acids, total BA (n= 6, 5). Data are represented as mean ± SEM. 
 
** P<0.01 NR vs. R, resp. using Unpaired Student’s T test. 
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5.2 Original research article: ““Body weight-dependent and –independent 
improvements in lipid metabolism after Roux-en-Y gastric bypass in a humanized 
murine model for the metabolic syndrome” 
 
This section contains an original research article that will be submitted to International Journal 
of Obesity in June 2018 and contains part of the studies performed for the completion of the 
present PhD thesis. 
 
 
My contribution, as first author of this article, includes the study design, data acquisition, data 
analysis and interpretation, and writing and revising the manuscript. 
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Abstract 
 
Background/Objectives: The incidence of the metabolic syndrome rapidly increases 
worldwide, and several biomarkers as increased total cholesterol and ceramide have been 
proposed to define the MetS risk. Roux-en-Y gastric bypass (RYGB) allows to achieve 
sustained and long-term weight loss and to improve comorbidities in the MetS. We elucidated 
whether improvements in lipid and glucose metabolism after RYGB surgery are body weight- 
dependent or not. 
 
 
Subjects/Methods: Male ApoE*3Leiden.CETP (ApoE3L.CETP) mice fed Western type diet 
for 6 weeks underwent RYGB or Sham surgery. Sham groups were either fed ad libitum group 
or body weight-matched (BWm) to the RYGB mice, to discriminate and identify surgical effects 
from body weight loss associated effects. Plasma was collected to assess the metabolic profile 
before and after surgery, and glucose tolerance and insulin sensitivity was tested before and 
after surgery. 20 days after surgery, mice were sacrificed, liver was collected to assess 
metabolic, histological and transcriptomic changes after surgery. 
 
 
Results: RYGB induced a greater reduction in body weight and total fat mass compared to 
BWm and Sham ad libitum mice (Sham AL). Total cholesterol, non high-density lipoprotein 
(non HDL-C) and ceramide were strongly reduced 20 days after surgery in RYGB compared 
to BWm mice. Glucose tolerance and insulin sensitivity improved 2 weeks after surgery in 
RYGB and BWm mice. Liver histology confirmed lipid reduction in RYGB and BWm mice while 
functional and transcriptomic data indicated modification in lipid metabolism. 
 
 
Conclusions: RYGB surgery improves glucose metabolism and greatly ameliorates lipid 
metabolism in part in a body weight-dependent manner. Given that ApoE3L.CETP mice were 
extensively studied to describe the MetS, and given that RYGB improved ceramide after 
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surgery, our data confirmed the usefulness of ApoE3L.CETP mice after RYGB in deciphering 
the metabolic improvements to treat the MetS. 
Introduction 
 
Obesity (BMI >30 kg/m2) is a major healthcare problem worldwide 1. Obesity and its 
comorbidities such as type 2 diabetes mellitus (T2DM) 2, hypertension, non- alcoholic fatty 
liver disease (NAFLD) 3, hypertriglyceridemia 4 and cardiovascular disease (CAD) 5 are part 
of the metabolic syndrome (or MetS) 5. 
 
Several rodent models of obesity have been used in the past decades trying to describe the 
consequences of a Western type diet on metabolism. However, animals like ob/ob mice 6, 
db/db mice 7 and Zucker rats 8 do not describe all aspects of the MetS and the underlying 
cause of their obesity differs from common obesity in people. The ApoE*3Leiden.human 
Cholesteryl Ester Transfer Protein (ApoE3L.CETP) mouse model better describes the 
physiology and pathophysiology of the MetS. Indeed, the ApoE3Leiden mutation 9, 10 and the 
introduction of the human CETP gene 10 allow these mice to have a humanized lipoprotein 
metabolism: hence they develop atherosclerosis when fed a high fat high cholesterol (HFHC) 
diet and show a human-like response when treated with statins 11, 12. Moreover, ApoE3L.CETP 
mice, as humans, present low serum levels of high density lipoprotein cholesterol (HDL-C) 
and high serum levels of very low density lipoprotein (VLDL) and low density lipoprotein 
cholesterol (LDL-C) when fed a HFHC diet. Increased concentrations of VLDL/LDL-C are the 
result of the transgene ApoE3Leiden that impedes the uptake of VLDL remnants by the liver 
9 while decreased HDL-C concentration is due to the introduction of the human CETP gene 
 
that is responsible for the transport of cholesterol ester from HDL to apolipoprotein-B (apo-B) 
containing lipoproteins in exchange of triglycerides (TG), leading to decreased HDL-C 10. 
 
Bariatric surgery, and in particular Roux-en-Y gastric bypass (RYGB) is the most effective and 
available therapy in the treatment of obesity and MetS 13, in terms not only of long-term 
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maintenance of body weight loss 14, 15, but also in terms of improved glucose homeostasis 16, 
and reduced CAD and NAFLD 17-19. Particularly relevant for us were the findings that several 
improvements after RYGB were achieved independently from changes in body weight 20, 21. 
Among them was the reduction in sphingolipids 20: indeed, it has been shown that changes in 
sphingolipids are involved in improvements in the pro-inflammatory state and insulin sensitivity 
22. 
 
 
 
The major aim of this study was to elucidate the effects of RYGB surgery on lipid and glucose 
metabolism in the ApoE3L.CETP mice. Our study emphasized the morphological and 
metabolic changes after RYGB surgery, in terms of blood parameters and extensive histology 
and metabolic liver analysis. 
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Material and Methods 
 
Animals and housing conditions 
 
All experiments were performed with male ApoE3L.CETP mice obtained from TNO (TNO, 
Innovation for Life, The Hague, The Netherlands) 10, 23. Upon arrival at our facility, mice aged 
17-20 weeks were group housed and kept at a room temperature of 21°C with a 12h light/dark 
cycle (light on 2:00am-2:00pm). Mice were given 2 weeks to acclimate to the new 
environmental and housing conditions, during which they were fed standard chow diet 
containing 4.5% fat (3436 Kliba Nafag, Kaiseraugst, Switzerland); after these two weeks, the 
mice were then switched to HFHC diet containing 60% fat and 0.25% cholesterol (D14010701, 
HFHC, Research Diets, New Brunswick NJ, USA). The HFHC diet was offered ad libitum for 
6 weeks to induce obesity prior to surgery, and the same diet was offered after surgery until 
the end of the experiments. Three days prior to RYGB or Sham surgery and three days after 
surgery, mice were switched back to chow diet to avoid peri-surgical complications. After 
surgery, mice were single housed until the end of the experiments. The Cantonal Veterinary 
Office of Zurich approved all the animal experiments (licence 122/2014). 
 
 
Bariatric surgery 
 
Mice were allocated to RYGB or Sham surgery according to their body weight. To increase 
survival rate, we performed RYGB surgery on mice with a body weight of 32-48 g. Mice were 
fasted overnight before surgery, and received subcutaneous injections of antibiotics (Baytril 
10mg/kg; Bayer, Lyssach, Switzerand) and analgesics (Metacam 2.5mg/kg, Boehringer, 
Ingelheim am Rhein, Germany) prior to surgery. Following anesthesia induction (3.5% 
isoflurane in room air at 0.8 L/min), mice were positioned in a supine position. Rectal 
temperature was monitored throughout and used to control the heating pad temperature 
(Heating Pad, Harvard Happaratus, Massachusetts, USA). Surgery was performed under 
continuous inhalation anesthesia (1.5% - 2% isoflurane in room air 0.8L/min) for the first and 
second cohort of animals and under injectable anesthesia for the third cohort (anesthesia 
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cocktail: 50 mg/kg Fentanyl, Fentanyl Sintetica, Sintetica SA, Switzerland; 5 mg/kg 
Midazolam, Roche, Switzerland; and 1.5 mg/kg Medetomidin,Virbac, Switzerland; all i.p.). 
Because there were no differences among the cohorts, data from all three cohorts were 
combined for further analysis. 
Gastric bypass surgery was adapted from Bruinsma et al 24 and Hao et al 25. Following a 1.5 
to 2 cm midline laparotomy from the xyphoid, the stomach was carefully isolated to avoid 
damage of gastric arteries and the vagus nerve, and transected just distal to the cardiac 
antrum to create a small gastric pouch. The jejunum was transected 7 to 8 cm from the pylorus 
of the stomach. An end-to-side anastomosis of the proximal end of the transected jejunum to 
the distal small intestine, approximately 20 cm from the cecum, formed the respective 
biliopancreatic limb and common channel. The alimentary, or Roux, limb of 5 to 6 cm was 
formed by an end-to-end anastomosis of the distal transected jejunum to the gastric pouch. 
For Sham-operated mice, an anterior gastrostomy with subsequent closure was performed. 
Following completion of surgery, inhalation anesthesia was discontinued, or an antagonist 
cocktail supplement including a pain-killer was administered (0.2 mg/kg Temgesic, Schering- 
Plough, USA; 0.5 mg/kg Flumazenil, Labatec-Pharma, Swizerland; and 3.5 mg/kg Atipamezol, 
Graueb, Swizerland; all i.p.), respectively. Mice then received a second dose of Metacam (2.5 
mg/kg i.p.) and 1 ml of warm saline, supplemented with 5% glucose. 
Mice continued to receive subcutaneous injections of analgesics (dosing as above), and 0.9% 
saline supplemented with 5% glucose daily for the first 3 days after surgery, antibiotics were 
injected only 1 day post-surgery (dosing as above). Post-operatively, mice were fed chow for 
3 days; starting from postoperative day 4, small amounts of HFHC diet were re-introduced to 
their diet. By post-operative day 8, mice were exclusively fed HFHC diet. RYGB and Sham ad 
libitum (Sham AL) had ad libitum access to food, while body weight matching (BWm) as part 
of the Sham operated mice, e.g. body weight-matched group (BWm) started on day 8 after 
surgery to allow mice to completely recover from the surgery beforehand. 
Body weight and food intake 
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Mice were single housed after surgery. Body weight was measured weekly prior to surgery 
and daily after surgery. Daily food intake was measured manually, 4h prior to dark onset and 
expressed as grams/day consumed. 
 
 
Body composition 
 
Total lean mass and subcutaneous and intra-abdominal fat mass were measured by 
quantitative microcomputed tomography (LaTheta LCT-100A scanner, Hitachi-Aloka Medical 
Ltd., Tokyo, Japan) on the carcasses of mice after sacrifice. Analysis was performed by 
LaTheta software (version 2.10, Hitachi-Aloka Medical Ltd., Tokyo, Japan) in the lumbar 
region between vertebrae L1-L5 from 1 mm slices images, 250 x 250 pixel size 26, 27. 
 
Lipid parameters 
 
Blood was collected from all mice in microvette Lithium-heparin (Sarstedt, Nümbrecht, 
Germany) prior to surgery from the sublingual vein and 3 weeks after surgery by cardiac 
puncture in a terminal experiment to perform lipid analysis. Blood was immediately centrifuged 
at 11’000 rpm at 4°C for 5 min, and heparin plasma was aliquoted and stored at -80°C until 
assayed. Total cholesterol (TC), HDL-C and TG were analysed via UniCel® DxC 800 
Synchron® Clinical System according to the manufacturer’s instructions. Non-esterified fatty 
acids (NEFA) (HR Series NEFA –HR, Wako, Virginia, USA) and beta-hydroxybutyrate (BHB) 
(Randox D-3-Hydroxybutyrate, Randoy Laboratories Ltd., Crumlin, County Antrim, United 
Kingdom) were analysed with the Cobas Mira Roche-Autoanalyzer (F. Hoffmann-La Roche 
Ltd., Basel, Switzerland), according to the manufacturer’s instructions. 
 
 
Sphingolipids measurements 
 
Analysis was performed via MS-LC system at the Institute of Clinical Chemistry, University of 
Zurich and University Hospital Zurich, Switzerland. A detailed description of the method is 
reported in the Supplementary Data. 
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Tissue histology 
 
All animals were deeply anesthetized with isoflurane and sacrificed via opening of the thoracic 
cavity and exsanguination by cardiac puncture; a complete necropsy was performed on each 
mouse. Tissue of interest (liver and pancreas) were removed and fixed in 10% neutral- 
buffered formalin (Formafox, Hittmau, Switzerland) or snap-frozen. Formalin-fixed samples 
were trimmed according to guidelines 28, dehydrated through graded alcohols and routinely 
paraffin wax embedded. Consecutive sections (3-5 µm) were prepared, mounted on glass 
slides and routinely stained with hematoxylin eosin (HE). 
Microscopic findings in the HE-stained livers slides were classified with standard pathological 
nomenclature and severities of findings were graded on a scale of 0 to 4 (no finding present 
0, minimal 1, mild 2, moderate 3, or severe 4). Grades of severity for microscopic findings 
were subjective; minimal was the least extent discernible and severe was the greatest extent 
possible 29. 
Oil red O (ORO) staining was performed on snap-frozen crymold-embedded livers (see 
supplementary data). Briefly, a threshold classification allowed recognition of positive (red) 
hepatocellular cytoplasm and negative hepatic parenchyma, and the results were expressed 
as positive area versus total area in the whole liver section. 
Data are presented as average (± SEM) percentage of lipid-containing parenchyma in the 
group. 
Please see Supplementary Data for the description of pancreas histology. 
 
 
Triglycerides and non-esterified fatty acids in livers 
 
To measure liver TG content, approximately 50 mg of tissue was homogenized with 1 mL 2:1 
chloroform:methanol solution. The homogenate was centrifuged for 5 min at 2’500 rpm and 
the supernatant was collected and diluted with 0.9% NaCl. Samples were centrifuged for 5 
min at 2’000 rpm, then resuspended in a 1:1 methanol-H2O solution. The upper phase was 
discarded, then samples were dried and resuspended in dimethyl sulfoxide (DMSO). TG 
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content was measured with Cobas Mira Roche-Autoanalyzer (F. Hoffmann-La Roche Ltd., 
Basel, Switzerland), according to the manifacturer’s protocol. Liver NEFA content was 
measured following manifacturer’s indication with Free Fatty Acid Quantitation Kit (Merck 
KGaA, Darmstadt, Germany). 
 
 
Liver transcriptomics 
 
Analysis were performed at the Institute of Molecular Biology and Biotechnology, FORTH, 
University of Crete. A detailed description of the method is reported in the Supplementary 
Data. 
 
 
Glucose metabolism: oral glucose tolerance test and insulin sensitivity test 
 
Oral glucose tolerance (OGTT) and insulin sensitivity (IST) tests were performed in the same 
cohorts of mice at different time points prior to and after surgery. Before surgery, the tests 
were done when mice were chow fed (approx. 21 weeks of age) and after the switch to HFHC 
diet at 25-27 weeks of age, i.e. after approx. 6 weeks of HFHC exposure. OGTTs and ISTs 
were repeated 2 and 3 weeks after surgery, respectively, with one week of recovery in 
between. 
For OGTT, mice were fasted for 6h and briefly anesthetized with isoflurane (3% isoflurane in 
the induction chamber, 0.8L/min). A bolus of glucose (2g/kg) was given by oral application 
(gavage). Blood was sampled in microvette EDTA tubes (Sarstedt, Nümbrecht, Germany) by 
tongue bleeding at time 0 (i.e., just before gavage), 15, 30 min, and at time 45, 60, 90 and 120 
min by tail bleeding for glucose measurements (Breeze 2, Bayer Glucose Meter, Basel, 
Switzerland). For each mouse, the area under the curve (AUC) was calculated above its 
baseline. Blood was kept on ice and immediately centrifuged at 4°C for 5 min at 11’000 rpm. 
EDTA plasma was separated and stored at -80°C until assayed. For the OGTT test after 
surgery, mice were not anesthetized for tongue bleeding due to the high sensitivity of the 
RYGB mice to anesthesia. 
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ISTs were performed after 4h of fasting in the same cohort of mice. After a baseline blood 
sample from tail bleeding had been collected, Insulin Humalog (0.5U/kg, 100U.I./mL, Lilly, 
Genève, Switzerland) was injected intraperitoneally. After 15, 30, 45, 60, 90 and 120 min, 
blood glucose was measured by tail bleeding. Mice that became hypoglycemic (i.e. reached 
glucose values lower than 2.5 mmol/L) were immediately given a bolus of glucose (2g/kg) and 
were excluded from the current test. Since in our analysis mice became hypoglycemic only 
when chow fed, we excluded them only for this test but not when fed the HFHC diet. The AUC 
was calculated above each animal's individual baseline. 
 
 
Cytokines measurements 
 
At the time of sacrifice, i.e. 20 days after surgery, blood was collected by cardiac puncture in 
microvette EDTA (Sarstedt, Nümbrecht, Germany), immediately centrifuged at 11’000 rpm for 
5 min at 4°C, aliquoted and stored at -80 °C prior to analysis. Cytokines were measured with 
V-Plex Cytokine kit (Meso Scale Discovery, Gaithersburg, MD, USA) following the 
manufacturer’s protocol. 
 
 
Data Analysis and Statistics 
 
All data were expressed as mean ± standard error of the mean (SEM). One-way or 2 way- 
ANOVA followed by Bonferroni or Tukey post-hoc tests were used for comparison among the 
3 groups (RYGB, BWm and Sham AL), as appropriate. For all statistical analysis, a p-value 
lower than 0.05 was considered significant. Data were analysed using Prism GraphPad 8.0. 
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RESULTS 
 
RYGB mice have reduced body weight and food intake after surgery 
 
RYGB induced a marked body weight loss (Fig 1A) compared to Sham AL mice, which was 
significant starting from day 8 after surgery. 
Overall, RYGB-operated mice lost approx. 32% of their initial body weight 3 weeks after 
surgery, compared to a slight 9% weight loss in Sham AL mice. Weight loss in the BWm group 
(approx. 34%) was induced by food restriction (Fig 1B), to discriminate surgery-specific 
metabolic effects from effects induced by the body weight loss itself. Importantly, there was 
no difference in weight or weight loss in BWm compared to the RYGB mice at the time when 
metabolic testing was performed 2-3 weeks after surgery. The major body weight loss in 
RYGB mice was already seen during the first week after surgery (Fig 1A). The initial weight 
loss in the Sham AL group most likely was the result of the feeding regimen during the post- 
operative care period, which included 3 days of chow feeding. The lack of weight regain in 
Sham AL mice was probably due to post-surgical metabolic testing, including OGTT and IST; 
hence, in the second and third post-operative weeks, body weight was largely stable in the 
Sham AL group. 
Food intake in the three groups of mice is highlighted in Fig 1B which shows that during the 
first post-operative week, RYGB mice ate on average approx. 1.3 ± 0.1 g of food per day, 
similar to BWm (1.3 ± 0.2 g) and Sham AL (1.3 ± 0.1 g). Further, during the following two 
weeks, no differences in average daily food intake were found between RYGB and Sham AL 
mice, respectively, while BWm mice had to be severely food restricted for the entire 
experiment to maintain the same body weight as a RYGB mice. This highlights that the 
sustained weight loss in RYGB mice is not due to a sustained reduction in eating, which is 
similar to previous studies 30 but different from RYGB operated rats 21. 
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RYGB surgery induced reduction in fat mass without changing in lean mass 
 
Body composition analysis was performed 20 days after surgery, i.e. at the time when mice 
were sacrificed, and indicated that despite the lack of significant differences in lean mass 
among groups (Fig 1C), body fat was markedly reduced in RYGB mice (0.7 ± 0.1 g) compared 
to BWm (1.5 ± 0.3 g) and Sham AL mice (6.2 ± 0.2 g) (Fig 1D). The reduction in total fat mass 
in RYGB and BWm mice was due to a reduction in both subcutaneous and intra-abdominal 
fat depots (Fig 1D); despite a difference in total fat mass between RYGB mice and BWm mice, 
the relative reduction in the respective fat depots was similar. 
 
 
Lipid profile improved after RYGB surgery 
 
RYGB and BWm mice had significantly reduced plasma TC, non HDL-C, TG and NEFA 3 
weeks after surgery (Table 1). The reduction in TC and non HDL-C was significantly stronger 
in RYGB than in BWm mice. No differences were found for plasma HDL-C and BHB among 
groups. 
Among sphingolipds, RYGB surgery induced a reduction in ceramide, and deoxy-ceramide. 
Moreover, both RYGB and BWm mice showed a reduction in sphingomyelin, and also in 
dihydro-ceramide, sphingosin-1-phosphate and hexosylceramide but without reaching 
significance between BWm and Sham AL (Table 1). Deoxysphingoind base increased within 
body weight loss, without reaching significance in the comparison between BWm and Sham 
AL. No differences were found in dihydro deoxyceramide and sphingoid base among the three 
groups. 
Although body weight loss per se was sufficient to induce a reduction the majority of these 
parameters, the additional reduction in TC, non HDL-C and ceramide in the RYGB mice were 
most likely a consequence of modification in fat absorption after RYGB surgery and hence 
surgery specific. 
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Liver histology and physiology 
 
Livers from RYGB and BWm operated mice showed decreased lipidosis (0.3 ± 0.2 and 1.3 ± 
0.4, resp.) compared to Sham AL livers (3.8 ± 0.1) (Table 3 and Fig 2A-C). 
Histomorphometrical analysis of lipid droplets in liver sections stained with ORO confirmed 
this result, with livers from Sham AL mice showing higher proportions of fat content vs total 
parenchyma (60%) compared to BWm and RYGB operated mice livers (41% and 24% resp.) 
(Fig 2A-C inset, 2E). The grade of hepatic lipidosis correlated with TG levels (Sham AL 1.7 ± 
0.1 mg/dL/g, BWm 1.1 ± 0.2 mg/dL/g and RYGB 0.7 ± 0.1 mg/dL/g) and NEFA (Sham AL 52.4 
 
± 4.1 mol/L/g, BWm 43 ± 3.4 mol/L/g and RYGB 34.7 ± 3.3 mol/L/g) in livers of Sham AL, 
BWm and RYGB mice (Fig 2D, 2F). No differences were found in parameters of inflammation 
and hepatocellular eosinophilic cytoplasmic inclusions (Table 3). 
 
 
Liver transcriptomics 
 
Microarray analysis on liver samples revealed 1137 transcripts (656 upregulated, 481 
downregulated) in the comparison between RYGB and BWm and 506 transcripts (300 
upregulated, 206 downregulated) between RYGB and Sham AL. Ingenuity Pathway Analysis 
(IPA) indicated that the observed change in gene expression in the three different groups were 
mainly associated with lipid metabolism and energy production. Moreover, functional 
comparisons revealed that concentration of lipids, synthesis of lipids and steroid metabolism 
were the most affected biological aspects in the comparison between RYGB and Sham AL 
(Fig 3A). Cell movement and migration of cells appeared to be more active in RYGB compared 
to BWm (Fig 3B). Interestingly functions involved in “concentration of D-glucose” and “lean 
body mass” had a decreased z-score (≤ 2) implying a decreased activation state of these 
biological functions (Fig 3B) in RYGB mice compared to BWm and Sham AL. 
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Cytokines 
 
Plasma cytokines were measured in all group before and after surgery (Table 2). Cytokine 
levels before surgery did not show any differences among groups. IL-4 and KC/GRO 
(keratinocyte chemoattractant/growth-regulated oncogene) did not show any differences 
among group or surgery related differences. After surgery, IFN-g increased post-surgery in all 
groups; IL-10 and IL-5 increased in RYGB and BWm mice, while IL-12p70, IL-2 and IL-6 
increased only in the RYGB group. TNF-α increased post-surgery only in Sham AL group. 
 
 
RYGB mice improved glucose metabolism after surgery 
 
Oral glucose tolerance tests (OGTT) and Insulin sensitivity tests (IST) were performed before 
surgery, i.e. in 19-21 weeks old mice when chow fed, and again in 25-27 weeks old mice after 
switching to HFHC diet (Fig 1E-J). 
After 6 weeks of HFHC diet, mice showed impaired glucose tolerance (P< 0.001, Fig 1E) 
compared to chow fed mice. Already two weeks after surgery, glucose tolerance was improved 
in all groups (Fig 1F-G). Unexpectedly, glucose tolerance also improved in the Sham AL mice, 
despite the continued exposure to the HFHC diet (Fig 1E-F). This might have been due to the 
post-surgical feeding regimen because a marked reduction in caloric intake is known to 
improve glucose tolerance 31 or to the usage of isoflurane in the test before but not after 
surgery because it is known that isoflurane can induce increased in glucose levels 32. 
Nonetheless, even though RYGB and Sham AL mice had similar baseline glucose levels, 
RYGB mice glucose levels peaked much higher 15 min after the glucose bolus than the other 
groups, probably reflecting the rapid transit of glucose through the stomach remnant into the 
small intestine. BWm mice displayed lower baseline glucose levels (6.7 ± 0.8 mmol/L), which 
may be due to the restrictive feeding conditions. Glycaemia in RYGB mice normalized faster 
than in the other two groups; in other words, during the OGTT, glucose levels in RYGB mice 
glucose  presented  a  greater  decrease  (8.2  ±  0.9  mmol/L)  at  30  min  after  glucose 
administration, as compared to Sham AL (11.4 ± 0.5 mmol/L) and BWm (10.1 ± 0.6 mmol/L) 
96  
(P<0.05). At 120 min, blood glucose levels in BWm mice were lower (7.1 ± 0.7 mmol/L) than 
in RYGB (8.3 ± 0.9 mmol/L) or in Sham AL mice (9.9 ± 0.4 mmol/L; P<0.05). The difference 
between RYGB and Sham AL mice was then no longer significant. 
After 6 weeks of HFHC diet, mice showed reduced insulin sensitivity as compared to when 
they were chow fed (Fig 1H). 3 weeks after surgery, RYGB mice displayed improved insulin 
sensitivity as compared to Sham AL mice (P<0.05; Fig 1I-J). RYGB and Sham AL mice had 
slightly higher glucose baseline levels (8.8 ± 0.8 mmol/L and 8.5 ± 0.4 mmol/L) than BWm (6.8 
± 0.7 mmol/L), similarly to what has been shown in Fig 1F during the OGTT. Importantly, 15 
min after the insulin injection, glucose levels dropped markedly in RYGB mice and were similar 
to BWm, but lower compared to Sham AL (P<0.05; 7.1 ± 0.4 mmol/L). RYGB mice maintained 
this lower glucose level until the end of the test (P<0.05; Fig 1I). BWm mice also maintained 
a lower glucose level which can be explained by the restrictive feeding condition throughout 
the post-operative period (Fig 1B, 1I). Thus, RYGB improved insulin sensitivity of mice fed 
HFHC diet fed compared to Sham AL mice, but the effect was similar in BWm mice which 
achieved the weight loss by food restriction. 
 
 
Functional pancreas data 
 
No major differences were found in pancreas histology and function. Please see 
Supplementary Data. 
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Discussion 
 
This study aimed to test the effect of RYGB surgery on lipid and glucose metabolism in male 
ApoE3L.CETP mice, a humanized mouse model used to assess the development and the 
mechanisms behind the MetS 11. We extensively investigated physiological changes in RYGB 
compared to BWm and Sham AL operated mice. The BWm group served as an additional 
control to discriminate the surgery-specific effects from body weight loss-induced effects. 
 
 
Many of our findings indicated that changes in lipid and glucose metabolism were mainly body 
weight loss dependent; we showed that the marked body weight decrease in RYGB and in 
BWm mice was related to the reduction in lipid parameters and improvement in glucose 
metabolism. However, more interesting was the finding that RYGB surgery reduced total fat 
mass, TC, non HDL-C, ceramide, and deoxyceramide plasma levels more than in BWm mice, 
i.e. at least in part independent of the body weight loss. This indicates that physiological 
changes after RYGB surgery have a specific effect at least on some aspects of lipid 
metabolism. 
Hence, our findings underline the importance of a caloric restriction to improve many aspects 
of lipid and glucose metabolism, but also reveal the specific effect of RYGB surgery in reducing 
the concentration of non HDL-C and several sphingolipids in plasma. 
 
 
Although data in literature had shown improvements of lipid parameters independently from 
body weight loss after bariatric surgery 20, 21, other studies performed in vivo and in humans 
support our data that improved lipid and glucose parameters are to some extent a 
consequence of the caloric restriction in the post-surgical period and the resulting body weight 
loss 33, 34. 
 
 
We showed that body weight loss in RYGB operated mice lasted for 16 days before reaching 
a plateau, and spontaneous food intake was reduced only in the first week post-surgery before 
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reaching similar food intake as in Sham AL group. BWm mice, instead, had to be strongly food 
restricted throughout the entire post-surgical period to achieve similar body weight to RYGB- 
operated mice. The body weight loss correlated in both RYGB and BWm groups with a 
significant reduction in total fat mass, but the effect for total fat mass was stronger in RYGB 
mice, even though the reductions in subcutaneous and intra-abdominal fat mass were not 
significantly larger than in BWm mice. Considering the similar food intake in RYGB and Sham 
AL mice, we believe that RYGB mice maintained lower body weight and fat mass mainly 
because of their increased energy expenditure, and perhaps in part increased faecal energy 
loss because of the use of the HFHC diet 30. For experimental reasons, we could not assess 
energy expenditure in our experiment but data from Nestoridi et al 35 supports this hypothesis; 
they had suggested that the observed increased in energy expenditure directly contributes to 
the RYGB-induced body weight loss. They also showed that increases in thermogenesis and 
in resting energy expenditure are associated with increased food consumption and significant 
body weight loss in RYGB mice 35. Furthermore, they also observed increased food intake and 
maintained body weight loss starting from the second week after surgery in the RYGB group 
35, similar to what we also showed. Finally, our findings were also similar to the study reported 
 
by Hao et al 30 in terms of body weight loss, body composition and food intake among the 
corresponding experimental groups. 
 
 
Even though body weight loss directly correlated with the decrease of some lipid parameters 
 
21, 36-38, a further decrease in TC and non-HDL-C levels in RYGB mice compared to BWm mice 
already 20 days after surgery indicated the presence of a direct surgical effect 14. Even if we 
could not prove the presence of a direct surgery specific mechanism to explain the differences 
found between RYGB and BWm, we hypothesized that changes in lipid absorption 39, mainly 
due to a reduction in cholesterol absorption and increased faecal levels after RYGB  surgery 
40, 41 could well explain the reduction seen in our lipid parameters. 
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We did not see an improvement in HDL-C levels in the time-frame of our studies, e.g. 20 days 
post-surgery, but other studies in rats had also reported changes in HDL-C only after 20 weeks 
post-surgery 42, and in humans 1 year after surgery 43. 
 
An interesting effect of RYGB in our ApoE3L.CETP mice was the reduction in ceramide and 
deoxy-ceramide. Actually alterations in ceramide levels have been related with MetS 44. 
Particularly, increased ceramide were found to correlated with in increased CAD risk 45 and 
atherosclerosis 46. Moreover, a correlation between elevated ceramide and obese subjects 
with T2DM was demonstrated as well by Haus et al 47. 
Our data are consistent with human studies that also showed reduced ceramide 1 month  20,  
and 3 and 6 months after RYGB 22, 44. 
 
It is well established that the reduction in body weight and the improvement in lipid metabolism 
after RYGB directly impact liver histology and liver functionality 48, 49. This was confirmed by 
our study because the histological liver findings at the time of sacrifice paralleled the 
improvement in metabolic parameters; hepatocellular lipidosis and liver TG levels were 
reduced in RYGB and BWm mice compared to Sham AL mice. A slight increase in 
inflammatory parameters was observed in RYGB mice which may have been associated to 
the rapid body weight loss 50, 51, but we did not observe any differences between BWm and 
RYGB regarding these parameters. Thus, most of these effects may be solely due to the body 
weight loss. 
 
 
Overall, the functional analysis of liver metabolism was in line with the histological and 
physiological changes after RYGB. 
Albeit systemic cytokines measurements showed no difference among groups before surgery, 
we saw a minor increase in some cytokines without any specificity group-related. We believe 
that a general pro-inflammatory state is one of a causative factors of the MetS in obesity 52 
100  
and that a higher level of inflammation post-surgery could be a consequence of the surgical 
procedure and modification in the adipose tissue 53. Importantly, metabolic parameters 
improved despite the slight increase in some inflammatory parameters. 
 
 
Finally, we showed that already 2 weeks after surgery, RYGB-operated ApoE3L.CETP mice 
had significantly improved glucose tolerance and insulin sensitivity as it has been shown 
previously 33, 54, 55. In addition, the major contribution to the improvement of glucose 
metabolism was due to the amelioration in insulin sensitivity in RYGB mice 56, 57. Interestingly, 
caloric restriction after surgery may have been a major driver in these effects because the 
same was shown in BWm mice; this is consistent with previous studies that had also 
demonstrated that improved glucose metabolism is at least to some part due to reduced 
caloric intake in the immediate post-surgical period and the RYGB-induced weight loss 31.. 
According to the so-called foregut hypothesis, the bypass of duodenum and the proximal 
jejunum after RYGB surgery reduced insulin resistance, hence glucose metabolism improved 
58. 
 
 
 
In summary, our findings confirmed the importance of RYGB surgery to improve lipid and 
glucose metabolism in part in a body weight loss dependent and in part in a non -weight loss 
dependent manner. To our knowledge, these experiments demonstrate for the first time the 
effect of RYGB on the reduction in ceramide levels in a murine model for the MetS. 
Since the ApoE3L.CETP mouse model is extensively studied to describe the MetS 11, 
particularly the atherosclerosis aspect 59 and since ceramides are considered a potential 
biomarker for atherosclerosis 44 we believe that our data provided an important proof-of- 
concept to the advantage of using the ApoEL.CETP mouse model after RYGB in deciphering 
the metabolic improvements after bariatric surgery to treat the MetS. 
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Figure legend 
 
Fig 1: (A) Body weight in Sham ad libitum (Sham AL, n=14), body weight-matched (BWm, 
n=11) and Roux-en-Y gastric bypass (RYGB, n=14) operated ApoE3L.CETP male mice. 
RYGB and BWm decreased body weight by more than 30% compared to the initial values. 
Imposed food restriction in BWm mice started on day 8 after surgery. 
(B) Average daily food intake in Sham AL (n=14), BWm (n=11) and RYGB (n=14) groups in 
the first three post-operative weeks. BWm mice were food restricted in the 2nd and 3rd week 
post-surgery to maintain the same body weight as RYGB operated mice. Importantly, no 
difference in spontaneous average food intake was found between RYGB and Sham AL mice 
at any time after surgery. 
(C-D) Body composition analysed by quantitative microcomputed tomography (LaTheta LCT- 
100A scanner, Hitachi-Aloka Medical Ltd., Tokyo, Japan). (C) Lean mass was similar in all 
groups, total fat mass was higher in Sham AL (n=12) compared to BWm (n=9) and RYGB 
(n=12) mice, and (D) the ratio of subcutaneous versus intra-abdominal fat was similar among 
the groups. (E-G) Oral glucose tolerance test (OGTT; 2 g/kg) performed when mice were 
chow fed (n=34) or after 2 months of high fed diet + 0.25% cholesterol (HFDC, n=34); (F), and 
2 weeks after surgery (n=13, 10, 11); (G) area under the curve (AUC) over 120 min was 
calculated during the OGTT, above baseline of each respective animal. (H-J) Insulin sensitivity 
test (0.5U/kg i.p.) performed when mice were chow fed (n=27) or after 2 months of HFDC 
(n=32) (H), and (I) 3 weeks post-surgery (n= 12, 10, 8); area under the curve (AUC) over 120 
min was calculated during the IST, above baseline of each respective animal (J). 
Data are means +/- SEM. Parameters with differing superscripts differ from each other at the 
P< 0.05 levels by post hoc Bonferroni adjustment when significant intergroup differences were 
found by one-way ANOVA (B, C, D, G and J) and 2-way ANOVA (A, E, F, H, I). **, P< 0.01, 
***, P < 0.001. 
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Fig 2: (A, C, E) HE-stained liver sections from (A) Sham AL, (C) BWm and (E) RYGB operated 
mice after 9 weeks of HFHC diet, scale bar = 100 µm. Insets: Oil red O (ORO) stained liver 
sections from the same mice; ORO-positive lipid content in the hepatocytes is decreased in C 
and E compared to A. (B) Triglyceride levels in liver extracts from Sham AL (n=13), BWm 
(n=9) and RYGB mice (n=11) after sacrifice; (D) quantification of the ORO staining in Sham 
AL (n=8), BWm (n=7) and RYGB (n=7) and (F) liver non-esterified fatty acids in Sham AL mice 
(n=13) and BWm mice (n=11) RYGB mice (n=11). Data are represented as mean ± SEM. 
Parameters with differing superscripts differ from each other at the P< 0.05 levels by post hoc 
Bonferroni adjustment when significant intergroup differences were found by one-way ANOVA 
(B, D, F). 
 
 
Fig 3: Heatmaps of the p-value (purple) or heatmap of the z-score as predictive or the 
increased functional activity (orange) or decreased functionality (blue). Data represents 
comparisons between RYGB (n=6) vs BWm (n=5) or RYGB vs Sham AL (n=5). 
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Table 1. Lipid parameters post-surgery in Sham ad libitum (Sham AL=12), Body weight- 
matched (BWm=11) and Roux-en-Y gastric bypass (RYGB=11) operated 
ApoE*3Leiden.CETP male mice 
 
 Sham AL BWm RYGB 
TC (mg/dL) 261 ± 13 a 218 ± 10 b 109 ± 5 c 
Non HDL-C (mg/dL) 216 ± 15 a 124 ± 13 b 70 ± 5 c 
HDL-C (mg/dL) 45 ± 3 a 42 ± 5 a 38 ± 4 a 
TG (mg/dL) 269 ± 34 a 114 ± 27 b 110 ± 17 b 
NEFA (µmol/L) 1073 ± 52 a 764 ± 55 b 697 ± 78 b 
BHB (mmol/L) 204 ± 64 a 246 ± 75 a 153 ± 27 a 
Cer (µM) 3.9 ± 0.2 a 3.4 ± 0.3 a 2.4 ± 0.1 b 
dhCer (nM) 445 ± 78 a 213 ± 70 a,b 166 ± 27 b 
doxCer (nM) 687 ± 37 a 581 ± 50 a 405 ± 32 b 
dh-doxCer (nM) 29.4 ± 3.5 a 22.5 ± 3.4 a 29.1 ± 5.1 a 
hexCer (nM) 4.8 ± 0.6 a 3.7 ± 0.5 a,b 2.7 ± 0.1 b 
SM (µM) 176 ± 7 a 134 ± 10 b 107 ± 6 b 
S1P (nM) 599 ± 50 a 515 ± 41 a,b 409 ± 48 b 
SB (nM) 208 ± 12 a 206 ± 20.3 a 159 ± 4 a 
doxSB (nM) 13.5 ± 1.9 a 21.5 ± 3.2 a,b 23.9 ± 2.1 b 
 
Total cholesterol (TC), High density lipoprotein cholesterol (HDL-C), non-esterified fatty acids 
(NEFA), beta-hydroxybutyrate (BHB), ceramide (Cer), dihydroceramide (dhCer), 
deoxyceramide (doxCer), dihydro deoxyceramide (dh-doxCer), hexosylceramide (hexCer), 
sphingomyelin (SM), sphingosin 1-phosphate (S1P), sphingoid base (SB), and deoxy 
sphingoid base (doxSB). 
 
Data are presented as mean ± SEM. Parameters with differing superscript letters differ from 
each other at the P< 0.05 level by post hoc Bonferroni adjustment after significant intergroup 
differences were found by one-way ANOVA. 
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Table 2. Plasma cytokines levels (pg/mL) before (pre-op) and after (post-op) surgery in Sham 
ad libitum (Sham AL=8), Body weight-matched (BWm=7) and Roux-en-Y gastric bypass 
(RYGB=7) operated ApoE*3Leiden.CETP male mice. 
 Sham AL BWm RYGB 
Pre –op Post-op Pre -op Post-op Pre -op Post-op 
IFN-g 0.25 ± 0.02 a 0.58 ± 0.04 b 0.25 ± 0.03 a 0.61 ± 0.06 b 0.25 ± 0.02 a 0.72 ± 0.06 b 
IL-10 32.3 ± 3.2 a,b 38.9 ± 5.3 a 23.7 ± 2.0 b 33.6 ± 3.9 a,b 25.2 ± 1.9 a,b 38.4 ± 3.2 a,b 
IL12p70 49.8 ± 4.3 a,b 57.9 ± 4.0 a,b 44.9 ± 6.3 a,b 56.6 ± 4 a,b 39.9 ± 5.2 a 65.1 ± 5.7 b 
IL-1b 6.16 ± 1.75 a,b 1.49 ± 0.03 a 3.71 ± 0.81 a,b 2.25 ± 0.35 a.b 5.67 ± 1.53 a,b 9.91 ± 4.15 b 
IL-2 6.81 ± 0.42 a,b 7.54 ± 0.65 a,b 6.24 ± 0.51 a 6.52 ± 0.30 a,b 6.05 ± 0.29 a 8.73 ± 0.62 b 
IL-4 1.92 ± 0.17 a 1.97 ± 0.19 a 1.33 ± 0.16 a 1.87 ± 0.2 a 1.51 ± 0.36 a 1.81 ± 0.42 a 
IL-5 3.76 ± 0.42 a,b 3.58 ± 0.47 a.b 2.49 ± 0.27 a 4.15 ± 0.74 a.b 3.78 ± 0.73 a,b 4.95 ± 0.68 a.b 
IL-6 19.9 ± 1.5 a 35.7 ± 4.0 a 16.9 ± 2.1 a 32.5 ± 4.9 a 25.1 ± 5.2 a 57.2 ± 8.9 b 
KG/GRO 146 ± 19 a 160 ± 23 a 140± 19 a 144 ± 31 a 118 ± 30 a 106 ± 18 a 
TNF-a 16.7 ± 1.3 a,b 25.9 ± 4.1 b 14.4 ± 3.1 a 16.8 ± 1.9 a,b 14.4 ± 2.3 a 20.4 ± 2.6 a,b 
 
Data are represented as mean ± SEM. Parameters with differing superscript letters differ 
from each other at the P< 0.05 level by post hoc Tukey adjustment after significant intergroup 
differences were found by multiple comparisons 2-way ANOVA. 
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Table 3. Liver histological scores 28, 29 in Sham ad libitum (Sham AL=12), Body weight- 
 
matched (BWm=11), and Roux-en-Y gastric bypass (RYGB=11) operated 
ApoE*3Leiden.CETP male mice.     
  Sham AL BWm RYGB 
Age mice (weeks)  17-20 17-20 17-20 
Livern  12 11 11 
Hepatocellular lipidosis§  12/12 8/11 2/11 
Grade 0  0 3 9 
Grade 1  0 4 1 
Grade 2  0 3 1 
Grade 3  2 0 0 
Grade 4  10 1 0 
Average severity$  3.8 ± 0.1a 1.3 ± 0.4b 0.3 ± 0.2c 
Chronic Inflammation§  5/12 8/11 9/11 
Grade 0  7 3 2 
Grade 1  5 8 7 
Grade 2  0 0 2 
Grade 3  0 0 0 
Grade 4  0 0 0 
Average severity$  0.4 ± 0.1a 0.7 ± 0.1a,b 1.0 ± 0.2b 
Hepatocellular Eosinophilic Cytoplasmic 
Inclusions§ 
 11/12 10/11 9/11 
Grade 0  1 1 2 
Grade 1  11 9 8 
Grade 2  0 1 1 
Grade 3  0 0 0 
Grade 4  0 0 0 
Average severity$  0.9 ± 0.1a 1.0 ± 0.1a 0.9 ± 0.2a 
n: number of liver samples analysed, §: incidence of the findings, $: Average severity calculated 
as sum of all scores divided by the total number of liver samples analysed. 
 
Data are represented as mean ± SEM. Parameters with differing superscript letters differ 
from each other at the P< 0.05 level by post hoc Bonferroni adjustment after significant 
intergroup differences were found by one-way ANOVA. 
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SUPPLEMENTARY DATA 
 
Supplementary Material and Methods 
Sphingolipids measurements 
Analysis were performed via MS-LC system at the Institute of Clinical Chemistry, University 
of Zurich and University Hospital Zurich, Switzerland. 20 µL of heparin plasma were extracted 
following the MMC (Methanol:methyl-tert-butyl ether:chloroform method) protocol from 
Pellegrino et al 60 and analyzed. 1mL of Methanol / MTBE / Chloroform (MMC 1.33/1/1 v/v/v) 
mixture containing internal standards (D7-Sphinganine, D7-Sphingosine, Ceramide d18:0 / 
12:0, Ceramide d18:1 / 12:0, deoxy ceramide (doxCer) m18:0 / 12:0, doxCer m18:1 / 12:0, 
Sphingomyelin (SM) d18:1 / 12:0, Glucosylceramide (GluCer) d18:1 / 8:0, D7-Sphingosine-1- 
Posphate (S1P), Posphates (PA) 17:0 / 17:0, Phosphoethanolamine (PE) 14:0 / 14:0, Lyso- 
phosphoethanolamine (LPE) 17:1, Phosphoglycerols (PG) 17:0 / 17:0, Phosphocolines (PC) 
14:0 / 14:0, PC 24:0 / 24:0, Lyso-phosphocolines (LPC) 17:0) was added to the plasma and 
vortexed for 20 seconds. Then, the mixture was shaken for 20 min in an Eppendorf Thermo 
shaker at 37°C at 1400 rpm. Protein precipitate was pelleted by centrifuging for 5 min at 16000 
rpm at 24°C, and 1mL of the supernatant was transferred to a new tube. The solvent was dried 
under a stream of N2. For LC-MS analysis, the sample was re-suspended in 100 µL methanol 
and transferred to MS vial. For one run, 25 µL was injected into the LC system. 
For quality control, a pooled sample was made, taking additional 5 µL of each sample and 
 
combined with a pool. From the pool, 2.5 µL, 5 µL, 10 µL, and 20 µL were aliquoted to a new 
tube and filled with PBS to 20 µL. These control samples were treated the same as the rest of 
the samples for extraction. 
For chromatographic separation, a C18 Uptispere (120 Å, 5 μm, 125 × 2 mm) column 
(Interchim, Montluçon, France) was used. The following mobile phases were used: Eluting A: 
Water / Acetonitrile 80/20 v/v with 10mM ammonium Acetate and 0.1% formic acid and Eluting 
B: Isopropanol / Acetonitrile 80/20 v/v with 10mM ammonium Acetate and 0.1% formic acid. 
The gradient was started with 70% A and 30% B for 1.5 min and is increased to 100% B within 
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the next 17min. After the column is washed with 100% B for 7 min and re-equilibrated to 
starting condition within the next 5 min. Conditions were adopted from Basit et al 61. Samples 
were analyzed on a Q Exactive (Thermo, Reinach, BL, Switzerland) using a heated 
electrospray ionization (HESI) interface. For mass spectral detection in positive mode, the 
following parameters were set on the HESI source: spray voltage 3.5kV, a vaporizer 
temperature of 300°C, sheath gas pressure 20 AU, aux gas 8 AU and a capillary temperature 
of 320°C. The detector is set to an MS2 method using a top10 approach with a 140k resolution 
for full spectrum and 17.5k for MS2, where a full scan is followed by fragmentation spectra of 
the ten most intense ions per full scan with stepped collision energy between 25 and 30. For 
the selection of ions to be fragmented, a dynamic exclusion filter was applied which will 
exclude ions after fragmentation for 20 seconds. 
 
 
Liver and Pancreas histology 
 
All animals were euthanized by cardiac puncture 20 days after surgery and a complete 
necropsy was performed on each mouse. Organ of interest (liver and pancreas) were removed 
and fixed in 10% neutral-buffered formalin (Formafox, Hittmau, Switzerland) or snap-frozen. 
Formalin-fixed samples were trimmed according to guidelines28 , dehydrated through graded 
alcohols and routinely paraffin wax embedded. Consecutive sections (3–5 µm) were prepared, 
mounted on glass slides and routinely stained with hematoxylin eosin (HE) or subjected to 
immunohistochemical staining. Immunohistochemistry was employed on pancreas slices to 
semi-quantify insulin (A0564 DAKO, Agilent, Switzerland) and glucagon (A0565 DAKO, 
Agilent, Switzerland). 
Microscopic findings in the HE-stained livers slides were classified with standard pathological 
nomenclature and severities of findings were graded on a scale of 0 to 4 (no finding present 
0, minimal 1, mild 2, moderate 3, or severe 4). Grades of severity for microscopic findings 
were subjective; minimal was the least extent discernible and severe was the greatest extent 
possible 29. Oil red O (ORO) staining was performed on snap-frozen cryomold-embedded 
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livers. Liver sections were cut at 6 μm, mounted on glass slides and allowed to dry at room 
temperature. They were then rinsed briefly in 50% ethanol, incubated in a 60% aqueous ORO 
solution (375 mg Oil Red O [Merck KGaA, Darmstadt, Germany] in isopropanol) at room 
temperature for 20 min, rinsed again in 50% ethanol and counterstained with hematoxylin for 
2 min. ORO stained slides were scanned using a digital slide scanner (NanoZoomer-XR 
C12000, Hamamatsu Photonics K.K., Japan) and the fat content was calculated in the digital 
slides using the Visiopharm Integrator System (VIS, version 4.5.1.324, Visiopharm, Hørsholm, 
Denmark). Briefly, a threshold classification allowed recognition of positive (red) 
hepatocellular cytoplasm and negative hepatic parenchyma, and the results were expressed 
as positive area versus total area in the whole liver section. Data are presented as average (± 
SEM) percentage of lipid-containing parenchyma in the group. 
 
 
Islets isolation and Glucose-Stimulated insulin secretion 
 
After sacrifice, pancreas of few randomly selected mice was digested and islets were isolated 
following an islet isolation procedure adapted from Nordmann et al 62. Islets were let recover 
for 24h in a cell culture incubator (37°C, 20%O2 and 5%CO2) then hand picked and plated 10 
islets/well into a 24 well ECM plate (Novamed, Jerusalem, Israle) before performing glucose- 
stimulated insulin secretion (GSIS) test following a modified procedure from Rütti et al 63. 
Krebs-Ringer phosphate solution supplemented with 0.1% BSA and 1M Hepes (KRH) were 
used. Islets were preincubated for 30 min with KRH with 2.8 mM glucose at 37°C to let islets 
adapt to KRH solution before starting to collect the supernatant to measure insulin secretion. 
To measure basal insulin release, islets were incubated for 1h with fresh KRH + 2.8 mM 
glucose followed by 1h with KRH + 13.7 mM glucose in order to measure stimulated insulin 
release. At each incubation, supernatant was collected, immediately frozen and used to 
measure insulin. To quantify insulin content after the two incubations, islets were lysed with 
0.18M HCl in 70% EtOH at 4°C overnight. Insulin was measured with the Mouse Insulin ELISA 
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(Mercodia AB, Uppsala, Sweden) and insulin secretion was calculated as percentage of total 
insulin content. 
 
 
Supplementary result 
Pancreas 
Pancreas histological analysis did not show any differences among groups, e.g. for islets size, 
number of islets or quantity of glucagon/insulin in the islets. This is in agreement with our 
findings during static glucose stimulation in isolated islets from RYGB, BWm and sham AL 
mice at time of sacrifice. Static high glucose stimulation (13.7mM) increased insulin secretion 
in pancreatic islets isolated from all groups. Pancreatic islets isolated from sham AL mice 
showed the highest insulin secretion of 1.5 ± 0.2% compared to 0.5 ± 0.1% of RYGB and 1.2 
± 0.3 of BWM, despite similar levels of basal insulin secretion at 2.8 mM glucose. 
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Fig 1S: (A) Islets quantification by size from Sham ad libitum (Sham AL=3), body weight- 
matched (BWm=2) and Roux-en-Y (RYGB=2) male ApoEL.CETP operated mice. Islets above 
15000 µm2 were considered for this quantification. No difference was found among groups. 
(B) Insulin concentration relative to insulin content in islets from Sham AL, BWm and RYGB 
operated mice 3 weeks after surgery. After isolation, islets were let to recover for 24h then 
stimulated for 60 min with low (2.8 mM) and high (13.7mM) glucose solution, resp., to measure 
insulin secretion. Sham AL secreted more insulin compared to BWm and RYGB isolated islets. 
(C -D) Insulin staining and quantification in Sham AL, BWm and RYGB operated mice, scale 
bars = 100 µm. 
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(E-F) Glucagon staining and quantification in Sham AL, BWm and RYGB operated mice, scale 
bars = 100 µm. 
Data are represented as mean ± SEM. **, *** P<0.01 or 0.001, Sham AL vs BWm and RYGB, 
resp., after Paired Student’s T test (B) or after post hoc Bonferroni adjustment significant 
intergroup differences were found by one-way ANOVA multiple comparison (D-F); different 
letters indicate significant differences. 
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6 Discussion 
This dissertation project was part of RESOLVE, a consortium of 12 multidisciplinary teams of 
computational modellers, engineers, biomedical researchers and clinicians whose goal was 
to elucidate the underlying mechanisms that connect the main pathophysiological hallmarks 
of the MetS: low HDL-C, high triglycerides and loss of glycaemic control. Particularly, 
RESOLVE wanted to develop a computational modelling system able to combine outcome 
from pre-clinical and clinical research with network analyses to potentially identify new targets 
for the MetS, e.g. to develop new strategies or drugs to treat the MetS. 
As a matter of fact, the mathematical model is still under validation since it is quite difficult to 
translate animal model research directly to human research and to clinical applications; 
nevertheless, some aspects of the MetS could be validated with the computational model: for 
example, a new method to quantify the interaction between glucose and NEFA had been 
proposed [164], or a computational model to describe T2DM [165]. Another aspect that has 
been developped in this physiology-based dynamic model is a way to analyse postprandial 
glucose and insulin profiles, e.g. in situations of impaired glucose tolerance and insulin 
resistance (personal communication). 
 
RESOLVE in general and, particularly, in our part where we carried our pre-clinical studies 
using a humanized murine model, the ApoE3L.CETP mice, aimed to clarify the complex 
polygenic and multifactorial setting of the MetS as well as the pathogenic sequence in the 
development of insulin resistance and the high triglyceride/low HDL-C phenotype as well as 
their relationships. 
My contribution in the RESOLVE project aimed to investigate the physiological effects of 
RYGB in ApoE3L.CETP mice in order to produce computational model predictions that could 
eventually be verified in parallel studies conducted in MetS patients who underwent RYGB 
surgery by another partner of RESOLVE. 
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To provide these data, firstly, we characterized the effect of long-term access to a HFHC diet 
in the ApoE*3Leiden.CETP mice on feeding behaviour, glucose and lipid metabolism, 
highlighting the presence of two different phenotypes: responder and non-responder mice. 
Secondly, we deciphered the effects of RYGB surgery in obese male responder 
ApoE*3Leiden.CETP mice on glucose and lipid metabolism. Hence, we highlighted the 
relevance of surgery-specific effects compared to the pure body weight loss and caloric 
restriction mediated effects. 
 
 
Considering that individual studies have been discussed in detail in the respective sections, 
for this discussion part, I will briefly summarize the general conclusion and focus on potential 
future perspectives. 
 
 
It is well established that the obesity epidemic is increasing worldwide and that it is one of the 
main factors that contributes to and drives hypertension, elevated plasma insulin 
concentrations and insulin resistance (IR), and, eventually, T2DM, hypertriglyceridaemia and 
low HDL-C levels. All these mentioned factors are components of the MetS [14, 15]. 
Moreover, these symptoms are not only indicating some features of the MetS alone, but it has 
been shown that they are interconnected. For example, data in the literature indicated that 
T2DM patients might show features of dyslipidaemia [166], or that patients treated with statins 
showed increased T2DM incidence [167] or that elevated HDL-C may improve function and 
survival of pancreatic β-cells [168]. Even if this interconnection has been proven in many 
studies [166-169], up to now it is not known whether high triglycerides/low HDL-C causes IR 
or if it is the opposite, or even if they are both appear simultaneously. 
 
 
Compared to all the animal model used in obesity and MetS research [170], our ApoE3L.CETP 
mouse model is known to better describe the MetS in terms of both glucose and lipid 
metabolism in response to a Western type diet [30, 32, 46] than other available rodent models. 
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Furthermore, some degree of phenotypic heterogeneity was reported among age-matched 
ApoE3L.CETP mice kept under similar experimental conditions [46], and we clarified it by 
showing the presence of two different phenotypes: responder (R) mice and non-responder 
(NR) mice. Because the human population is highly heterogeneous, we consider the same 
feature in ApoE3L.CETP mice useful for its role in pre-clinical research. 
We highlighted in detail a distinction between R mice and NR mice responses to a HFHC diet. 
Mice classified as R mice, indeed, exhibited the features of the MetS: increased body weight, 
increased subcutaneous and intra-abdominal adipose tissues, increased plasma total 
cholesterol, triglycerides and HDL-C [30, 32, 46, 171], and reduced glucose sensitivity [172, 
173] compared to NR mice. Particularly, we confirmed that the separation between R mice 
and NR mice at an early stage based on triglycerides levels seemed to be generally predictive 
of the final phenotype, even though we observed also a certain degree of heterogeneity within 
our NR and R populations, respectively, and in our analysis in comparing NR mice and R 
mice; in other words, we pointed out a partial overlap between the two groups. 
A limitation in the use of NR mice in MetS studies found its explanation in liver histology: not 
only did NR mice exhibit reduced levels of lipidosis, but also showed prominent hepatic 
inflammatory and proliferative changes. These findings suggested that the hepatic pathology 
seen in NR mice may have a detrimental effect on hepatic function, making them unhealthy 
controls to the R mice; this needs to be considered when using these mice in studies of the 
MetS. 
 
 
Some aspects in the heterogeneity in this model, related to the responder mice, are also 
representative for the human situation with a very heterogenous patient population; in the first 
part of these studies using the ApoE3L.CETP mice we studied some reasons leading to this 
heterogeneity and are propose the introduction of other parameters such as liver histology for 
the final classification of these mice, in addition to circulating metabolites. 
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We therefore suggest that it is important to identify NR mice and to use them with caution; 
when assessing aspects of the MetS with R mice, appropriate controls should also be R mice, 
with potentially an additional control with NR mice, keeping the mentioned limitations in mind. 
It may also be suggested the use different controls such as chow fed R mice, huCETP mice, 
ApoE-/- chow and HFHC diet; other diet induced obese (DIO) mice [174] could also be used 
as an established model to define some aspect of the MetS. 
The second part of my dissertation aimed at clarifying the effects of RYGB in ApoE3L.CETP 
responder mice. Our findings confirmed the use of RYGB as a “golden standard” procedure 
in treating the MetS [119]. Particularly, we used the body-weight matched (BWm) mice as one 
of our control to be able to discriminate between pure body weight loss dependent effect from 
surgical effects. 
In our experimental setup, RYGB mice lost weight without altering their food intake, while the 
BWm mice had to be highly food restricted to maintain the same body weight as RYGB mice; 
the difference may be due to the increased energy expenditure in RYGB mice [132, 175]. This 
aspect is different from what has been shown in rats and in humans. In fact, RYGB operated 
rats had reduced food intake compared to Sham AL rats despite an increase in their energy 
expenditure [133, 176, 177]; in humans increased energy expenditure has been reported in 
some [178, 179], but not in all studies. 
In rodents or in humans, body weight loss also indicates a loss in fat mass [126, 180]. 
Typically, body weight and fat loss occurs immediately after surgery until a plateau is reached 
14 days after the surgery for rodents and around one year after surgery for humans [181]. 
 
Our results highlighted specific RYGB effects that appeared to be body weight loss dependent 
[97, 132, 136] and some other effects independent from body weight loss [135, 182]. 
In agreement with other studies, our results showed improvement in liver lipidosis [183], lipid 
metabolism [184, 185] and glucose metabolism [132, 186, 187], and these effects were 
dependent to body weight loss since they were also found in BWm mice. 
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Nonetheless, specific greater reduction in some lipid parameters such as total cholesterol and 
non HDL-C, in RYGB mice indicated a direct surgical effect independently from body weight 
loss [136]. We hypothesized that physiological changes in the gut, mainly in lipid absorption, 
i.e. reduced cholesterol uptake, could explain why RYGB operated mice may have had lower 
total cholesterol and non-HDL-C levels [142, 143]. 
Moreover, some sphingolipids, e.g. ceramide were highly reduced in RYGB mice similarly to 
what has been shown in human studies [155, 182, 188]. To us, this aspect was interesting 
because not only it has been shown that increased sphingolipids, especially ceramide, were 
correlated with obesity [155] and atherosclerosis [189, 190], but also that ceramide decreases 
after RYGB in humans [155, 182, 188]. Hence, this specific result underlined how important 
data can be translated from animal models to humans. Particularly, we believe that this is an 
important goal in the context of modelling metabolic data from a humanized animal model 
such as ApoE3L.CETP mice that can be used to predict human outcomes. 
 
Therefore, our data will help in the development of the computational model in RESOLVE and 
we could provide evidence confirming the importance of bariatric surgery in defeating the 
MetS. 
 
 
Based on our preliminary results and the consideration that RYGB improves insulin secretion 
[132, 191] and that HDL may also directly modulate glucose metabolism by influencing 
pancreatic β-cells [192, 193], further experiments could investigate how RYGB ameliorates 
functionality and viability of β-cells via HDL’s anti-apoptotic effect. This could perhaps include 
tests of whether islets function and viability are improved after RYGB, and on the other hand 
investigations whether HDL function is improved after RYGB. 
These future investigations will help to understand the effect of bariatric surgery on the function 
of pancreatic islets in general, and on the functionality of HDL lipoprotein in respect to HDL’s 
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role in modulating pancreatic islet cell viability. Hence, these experiments will provide a crucial 
missing piece that connects dyslipidemia and diabetes in obesity. 
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7 Abbreviations 
ApoE – apolipoprotein E 
 
BPD-DS – Biliopancreatic Diversion with Duodenal Switch 
CAD – Cardiovascular Disease 
CETP – Cholesterol Ester Transfer Protein 
GB – Gastric Banding 
HDL-C – High Density Lipoprotein Cholesterol 
HFHC – High Fat High Cholesterol 
IR – Insulin Resistance 
 
IST – Insulin Sensitivity Test 
 
LDL-C – Low Density Lipoprotein Cholesterol 
MetS – Metabolic syndrome 
NAFLD – Non-Alcoholic Fatty Liver Disease 
OGTT – Oral Glucose Tolerance Test 
RYGB – Roux-en-Y Gastric Bypass 
SG – Sleeve Gastrectomy 
 
T2DM – Type 2 Diabetes Mellitus 
TC - Total Cholesterol 
TG – Triglycerides 
 
VLDL – Very Low Density Lipoprotein 
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